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ABSTRACT 
Insulin Regulation of Reverse Cholesterol Transport 
Samuel Lee 
 
Insulin resistance and type 2 diabetes are pathogenetically linked to 
increased risk of cardiovascular disease. While insulin resistance is 
defined by a dysregulation in hepatic insulin signaling, it is unclear how 
this impairment relates to the development of cardiovascular disease. 
Recently, there has been evidence showing that in insulin resistant 
individuals, cardiovascular disease is associated with a defect in 
reverse cholesterol transport – the cardioprotective process by which 
excess cholesterol is removed from the periphery, and returned to the 
liver for biliary excretion. Reverse cholesterol transport is facilitated by 
high-density lipoprotein (HDL) metabolism. Thus, malfunction in HDL 
turnover during reverse cholesterol transport may contribute to the 
buildup of atherosclerotic plaques, and subsequent cardiovascular 
disease in insulin resistant individuals. In this thesis, we seek to 
establish a better understanding of HDL metabolism and reverse 
cholesterol transport, as they relate to key transcription factors that 
mediate hepatic insulin signaling, namely the insulin-repressible 
forkhead transcription factors, FoxO1, FoxO3, and FoxO4 (FoxOs). We 
demonstrate that mice with liver-specific triple FoxO knockout (L-
FoxO1,3,4) have increased HDL-cholesterol (HDL-C), associated with 
	
decreased expression of HDL-C clearance factors, scavenger receptor 
class B type I (SR-BI) and hepatic lipase, and defective selective 
uptake of HDL-cholesteryl ester by the liver. As such, we uncover a 
novel mechanism by which HDL-mediated reverse cholesterol 



















Table Of Contents 
 
List of Figures/Tables         v 
Acknowledgements          viii 
Dedication           xiii 
 
Chapter 1: General Introduction       1 
1.1.  General Overview of Thesis: Insulin Regulation of     
Reverse Cholesterol Transport      2 
1.2.  Insulin Signaling and Hepatic FoxOs     5
 1.2.1. The Insulin Signaling Pathway     5 
 1.2.2. Hepatic FoxO Regulation of G6pc and Gck   7 
1.3.  Cholesterol Metabolism        11 
1.3.1. Significance of Reverse Cholesterol Transport   11 
1.3.2. SR-BI         13 
1.3.3. Hepatic Lipase        20 
1.3.4. CETP         23 
1.4.  Hypothesis and Specific Aims       25     
 
Chapter 2: FoxO Transcription Factors are Required  
for Hepatic HDL-Cholesterol Clearance     28  
 
2.1. Introduction         29 
 
2.2. Results          31 
	ii	
2.2.1. Deletion of Hepatic FoxOs Increases Cholesterol 
Accumulation in Large HDL Particles     31 
2.2.2. FoxOs are Required for Expression of  
Scavenger Receptor SR-BI and Hepatic Lipase    33 
2.2.3. HDL Metabolism in L-FoxO1,3,4 and Control Mice  34 
2.2.4. HDL Metabolism in Primary Murine Hepatocytes  38 
2.2.5. Rescuing SR-BI Reverses the Accumulation of 
HDL-C in L-FoxO1,3,4 mice       39 
2.2.6. Acute Depletion of Hepatic FoxOs is Sufficient to  
Induce HDL Phenotype         40 
2.3.  Discussion          42 
2.4.  Materials and Methods        47 
 2.4.1. Mice and Diets        47 
 2.4.2. Plasma Lipoprotein Analysis      44 
 2.4.3. Gene Expression        44 
 2.4.4. SR-BI expression and HL activity     48 
 2.4.5. Radiolabeling of HDL       48 
 2.4.6. HDL Metabolism in Mice      50 
 2.4.7. Preparation of Murine Hepatocytes     52 
 2.4.8. Uptake Assay for Radiolabeled HDL with Hepatocytes 53 
 2.4.9. Motif Analysis        53 
2.4.10. Primer Sequences       54 
 2.4.11. Abbreviations        56 
 2.4.12. Statistical Analyses       56 
	iii	
 2.4.13. Study Approval        56 
2.5. Figures          57 
2.6. Supplemental Figures        65 
2.7. Tables          76 
 
Chapter 3: Other Contributors to Phenotype    80 
3.1.  Macrophage-to-Feces RCT in L-FoxO1,3,4 Mice    81 
 3.1.1. Macrophage-to-Feces RCT in WTD- and Chow-Fed Mice 81 
3.1.2. Defective Intestinal Cholesterol Reabsorption in  
L-FoxO1,3,4 Mice         82 
3.1.3. Potential Confounding Factors in Ezetimibe RCT Study 85 
3.2.  Hepatic FoxOs and Cholesteryl Ester Transfer Protein (CETP) 87 
 3.2.1. Role of CETP and Generation of L-FoxO1,3,4:CETPtg mice 87 
3.2.2. Analysis of plasma lipoproteins phenotypes in  
L-FoxO1,3,4:CETPtg mice       88 
3.3.  Sex Differences in L-FoxO1,3,4 Mice     89 
3.4.  Materials and Methods        90 
 3.4.1. Macrophage-to-Feces RCT in L-FoxO1,3,4 Mice  90 
  3.4.1.1. Ezetimibe Preparation     90 
  3.4.1.2. Macrophage Preparation     90 
  3.4.1.3. in vivo Phase       92 
  3.4.1.4. Radioactivity Measurements    94 
 3.4.2. Bile Acid Analysis in L-FoxO1,3,4 Mice    97 
	iv	
 3.4.3. Generation of L-FoxO1,3,4:CETPtg Mice    97 
 3.4.4. Male vs. Female L-FoxO1,3,4 mice     98 
3.5. Figures          99 
3.6. Supplemental Figure        110 
 
Chapter 4: Current Conclusions and Futures Directions  112 
4.1.  Macrophage-to-Feces RCT in L-FoxO1,3,4 mice    113 
4.1.1. Intrahepatic Cholesterol Sensing and Regulation  113 
4.1.2. Additional Confounding Factors     114 
4.1.3. Summary of Cholesterol Phenotypes    116 
4.2. Hepatic FoxOs and Cholesteryl Ester Transfer Protein (CETP) 117 
4.3.  Sex Differences in L-FoxO1,3,4 Mice     119 
4.4.  Final Remarks         120 
4.5. Figures          122 
 
References          125 
 





List of Figures/Tables 
Chapter 2 
 Figures 
 Figure 2.1. Plasma Cholesterol Profiles of Chow-fed and  
WTD-fed L-FoxO1,3,4 Mice       58 
Figure 2.2. Defects in HDL Metabolism Genes Due to  
Ablation of Hepatic FoxOs        59 
Figure 2.3. Plasma Decay Kinetics of  
125I-TC-/[3H]CEt-WT-HDL in Chow-Fed L-FoxO1,3,4 Mice   60 
Figure 2.4. Plasma-FCRs and Tissue Tracer Uptake Rates  
for 125I-TC-/[3H]CEt-WT-HDL in Chow-Fed L-FoxO1,3,4 Mice  61 
Figure 2.5. Uptake of 125I-TC-/[3H]CEt-WT-HDL by  
Hepatocytes Isolated from Chow-Fed L-FoxO1,3,4 Mice   62 
Figure 2.6. SR-BI Adenovirus in WTD-fed L-FoxO1,3,4 Mice  63 
Figure 2.7. Acute Knockdown via Cre Adeno-Associated virus  
in Chow-fed Hepatic FoxO Floxed Mice      64 
Supplemental Figures 
 
S2.1. Western Blot of “LDL” Fractions And  
Total Plasma apoA-I. Related to Figure 2.1.    66 
S2.2. Western Blot of Liver ABCA1 and SR-BI from Chow-Fed  
and WTD-Fed L-FoxO1,3,4 Mice. Related to Figure 2.2.  67 
S2.3. Plasma Decay Kinetics of 125I-TC-/[3H]CEt-WT-HDL in  
WTD-Fed L-FoxO1,3,4 Mice. Related to Figure 2.3.   68 
 
S2.4. Plasma-FCRs and Tissue Tracer Uptake Rates for  
125I-TC-/[3H]CEt-WT-HDL in WTD-Fed L-FoxO1,3,4 Mice.  
Related to Figure 2.4        69 
Figure S2.5. Adrenal Gene Expression in Chow-Fed  
L-FoxO1,3,4 Mice. Related to Figure 2.4.     70 
	vi	
 
Figure S2.6. Kinetics of Uptake of 125I-TC-/[3H]CEt-WT-HDL  
by Hepatocytes Isolated from Chow-Fed L-FoxO1,3,4 Mice.  
Related to Figure 2.5.        71 
Figure S2.7. Effect of SR-BI Adenovirus on HL in WTD-fed  
L-FoxO1,3,4 Mice. Related to Figure 2.6.     72 
Figure S8. Potential FoxO Binding Site Analysis of  
Scarb1 and Lipc Using HOMER Motif Discovery Algorithm  73 
Figure S2.9. Cholesterol Levels in Plasma Fractionated by  
FPLC in Chow-fed Hepatic FoxO Floxed Mice Transduced with  
Liver Specific Adeno-Associated Virus Expressing Cre.  
Related to Figure 2.7.        74  
Figure S2.10. Western Blot of Liver PDZK1 from WTD-Fed  
L-FoxO1,3,4 Mice and Hepatocytes Isolated from  
L-FoxO1,3,4 mice. Related to Figure 2.7.     75 
Tables 
Table 2.1. L-FoxO1,3,4 Microarray From Liver Tissues  77 
Table 2.2. Plasma-FCRs and Tracer Uptake Rates by Tissues for   
125I-TC-/[3H]CEt-WT-HDL in Chow-Fed L-FoxO1,3,4 mice  78 
Chapter 3 
 Figures 
 Figure 3.1. Macrophage-to-Feces RCT in WTD-fed  
L-FoxO1,3,4 Mice         100 
Figure 3.2. Macrophage-to-Feces RCT in Chow-fed  
L-FoxO1,3,4 Mice         101 
Figure 3.3. Total Bile Acid Pool Analysis in L-FoxO1,3,4 Mice 102 
Figure 3.4. Ezetimibe Treatment in C57BL/6 Mice   103 
Figure 3.5. Macrophage-to-Feces RCT in Chow-fed  
L-FoxO1,3,4 mice ± Ezetimibe Treatment     104 
	vii	
Figure 3.6. Liver Data Revisited from Macrophage-to-Feces  
RCT in Chow-fed L-FoxO1,3,4 Mice ± Ezetimibe Treatment  105 
Figure 3.7. Hepatic Gene Expression from Macrophage-to-Feces  
RCT in Chow-fed L-FoxO1,3,4 Mice ± Ezetimibe Treatment  106 
Figure 3.8. Generation of L-FoxO1,3,4:CETPtg Mice    107 
Figure 3.9. Plasma Cholesterol Profiles of Chow-fed  
L-FoxO1,3,4:CETPtg Mice        108 
Figure 3.10. Sex Differences in L-FoxO1,3,4 Mice    109 
Supplemental Figure 
S3.1. Proposed Model of Intestinal Radiolabeled Cholesterol 




 Figure 4.1. Potential Confounder: Differences in  
Tracer Specific Activity        123 
Figure 4.2. Potential Confounder: Unequal Injection of  











This thesis could not have been possible without the help of many different 
people, labs, and organizations. I would first like to gratefully acknowledge 
my doctoral mentor, Rebecca Haeusler. I am honored to be Dr. Haeusler’s 
first student, and am extremely thankful for her sharing this FoxO project 
with me, and allowing me to be a part of something truly special. I am also 
humbled by Dr. Haeusler’s scientific prowess, compassion for others, and 
ability to keep me motivated throughout this journey. She has developed my 
passion for science, and has given me the opportunity to take this passion 
with me towards my future goals. 
 
With the lab in mind, I would also like to acknowledge all the current and 
former “Haeuslerians” for all their assistance with experiments, intellectual 
conversations, and insightful wisdom: Enrico Bertaggia, Tiara Ahmad, Conchi 
Izquierdo, Sei Higuchi, Anna Chen, Clarence Manuel, Niroshan 
Shanmugarajah, Chen Zhao, Allison Hung, Kendra Zhong, Gabriella Belnavis, 
Caroline Conners, Jill Shah, Nikolaus Rasmus, Sara Shanaj, Nushrat 
Chowdhury, Madeline Zoltek, Jill Shah, Neyanel Vasquez, Daniel Cohen, 
Sabela Diaz-Castroverde, Jessie Lee, and Ido Haimi. I would especially like 
to thank Enrico for reminding me of every lab condition and machine setting 
there is, and not killing me even when I asked the same question for the 
millionth time – a true friend. I would also like to especially thank my 
	ix	
student, Gabi, for all her technical help and fearless approach to even the 
most daunting experiments. 
 
Next, I would like to acknowledge Mimmo Accili. As Dr. Haeusler’s former 
mentor, Dr. Accili has been somewhat of a grandfather figure to me, and as 
such, has imparted great wisdom and guidance. However, I am sure that 
many would agree that it’s Dr. Accili’s kindness (and sartorial fashion sense) 
that makes him unique – a gentlemen and a scholar. From Dr. Accili’s lab, I 
would like to especially thank Tommy Kolar and Ana Flete for all their 
technical expertise and assistance with mouse work, equipment, and pretty 
much being the glue keeping things together when things go wrong. I would 
also like to thank Joshua Cook, a former student of Dr. Accili’s (and 
hopefully PI of his own lab someday), for teaching me many complicated 
techniques and imparting me with plenty of extremely thorough protocols 
that I still refer to today. Thank you for being a great example and a great 
friend. 
 
I would like to thank many others at Columbia and elsewhere that helped 
me with either some part of this thesis or my scientific and personal 
development. This includes Rudy Leibel and the members of his lab, 
especially Charles LeDuc; Utpal Pajvani and the members of his lab, 
especially Alberto Bartolome and Kyeong Jin Kim; Henry Ginsberg and the 
	x	
members of his lab, especially Jing Liu; Ira Goldberg and the members of his 
lab, especially Diego Scerbo, Florian Willecke, Joe OBunike, and Chad Trent; 
Alan Tall and the members of his lab, especially Joanne Hsieh, Marit 
Westerterp, Nan Wang, Matthew Molusky, and Dave Thomas; Rajasekhar 
Ramakrishnan; and our collaborators in Hamburg, Germany: Franz Rinninger 
and Joerg Heeren and the members of their labs, especially Markus Heiene. 
 
During my time at Columbia, I was fortunate enough to partake in a number 
of part-time jobs that have helped me both financially and personally in 
terms of my career interests and communication skills. I would like to thank 
Ronald Liem and Steven Spitalnik for allowing me to be a teaching assistant 
for the Mechanisms of Human Disease course for four years. I would also 
like to thank Katherine Xu for being such a helpful co-TA, and a good friend.  
Next, I would like to thank Wendy Chung and Teresa Lee for giving me an 
opportunity to be a heart and lung transplant tissue harvester for the last 
seven years. I am going to miss waking up at 4 AM to go pick up heart 
tissues in the O.R. – something I will remember for the rest of my life. 
Finally, I would like to thank Columbia Technology Ventures and their 
management team, especially Liz Beerman, Brady Butterfield, and Orin 
Herskowitz. I am grateful to be a part of the CTV team for the past three 
years, where I learned so much outside the lab setting, especially how to 
write a good email. 
	xi	
I would like to gratefully acknowledge my dissertation committee members: 
Rebecca Haeusler, Richard Deckelbaum, Li Qiang, Mimmo Accili, Ira 
Goldberg, Henry Ginsberg, and Utpal Pajvani. I am in debt to your all your 
input and encouragement over the years. In addition, research cannot come 
without funding, and as such, I would like to thank my funding source, the 
NIH Ruth L. Kirschstein Predoctoral Individual National Research Service 
Award (F31HL132484). 
 
Finally, I would also like to officially acknowledge all of the authors of our 
manuscript (Chapter 2): Markus Heine, Christian Schlein, Rajasekhar 
Ramakrishnan, Jing Liu, Gabriella Belnavis, Ido Haimi, Alexander W. Fischer, 
Henry Ginsberg, Joerg Heeren, Franz Rinninger, and Rebecca A. Haeusler. 
For this manuscript, the authors gratefully acknowledge Alan Tall (Columbia 
University), Marit Westerterp (Columbia University and University of 
Groningen), Richard Deckelbaum, Domenico Accili, and Utpal Pajvani from 
Columbia University for their insightful comments. We also acknowledge the 
technical assistance of S. Ehret, E.M. Azizi, B. Henkel, M. Thiel (all from 
University Medical Center Hamburg Eppendorf, Hamburg, Germany), J. Lee, 
T. Kolar, and A. Flete (all from Columbia University). We thank Richard E. 
Morton and Diane Greene from the Cleveland Clinic, Cleveland, OH, USA, 
who donated CETP for radiolabeling, and Ira Goldberg, Joseph Obunike (both 
from New York University), David Thomas, and Matthew Mollusky (both from 
	xii	
Columbia University), who provided experimental advice. This work was 
funded by the NIH R01HL125649 (to Rebecca Haeusler), F31HL132484 (to 
Samuel Lee), and R35HL135833 (to Henry Ginsberg); the New York 
Community Trust P16-000716 (to Rebecca Haeusler); the German Diabetes 
Association (DDG) (to Franz Rinninger); Muehlbauer Stiftung, Hamburg (to 
Marcus Heine); the DFG (HE3645/7-1) and the EU FP7 project RESOLVE 
(FP7-HEALTH-2012-305707) (to Joerg Heeren); and D.A.C.H. Gesellschaft 




















I dedicate this thesis to the people that have given me the opportunities to 















1.1. General Overview of Thesis: Insulin Regulation of Reverse 
Cholesterol Transport 
The peptide hormone insulin directs a complex signaling cascade that 
regulates many aspects of glucose and lipid metabolism. Insulin is produced 
in the pancreas, and is secreted by pancreatic β-cells primarily in response 
to glucose, while other nutrients such as free fatty acids and amino acids can 
augment glucose-induced insulin secretion (1). There are also additional 
mechanisms that enhance the secretion of insulin, including the “incretin” 
hormones from the gut epithelium (2). As insulin circulates in the 
bloodstream, it reaches major tissues whose cells express the insulin 
receptor. While virtually all mammalian cells possess insulin receptors and 
respond to insulin, the major tissues targeted by insulin’s effect on 
metabolism include: muscle, where insulin promotes glucose uptake and 
protein synthesis; adipose tissue, where insulin promotes glucose and fatty 
acid uptake and inhibits lipolysis; neurons, where it 
promotes anorexigenic and locomotor signals; and most notably the liver, 
where insulin promotes glucose utilization, suppresses glucose production, 
and promotes triglyceride synthesis (3).  
 
The binding of insulin to hepatic insulin receptor activates a complex 
signaling cascade that fine-tunes both glucose and lipid levels in the blood. 






signaling in order to maintain energy homeostasis. Key components 
downstream of hepatic insulin signaling are the insulin-repressible forkhead 
transcription factors of the FoxO sub-family, FoxO1, FoxO3, and FoxO4 
(FoxOs), as will be discussed in greater detail.  
 
The liver also plays an essential role in cholesterol metabolism.  One 
important aspect is to facilitate the clearance of cholesterol from circulating 
high-density lipoprotein (HDL) particles into the liver, where it can be 
converted to bile acids or transported directly into the bile to be excreted in 
the feces (4, 5). HDL-cholesterol (HDL-C) is primarily cleared by the 
scavenger receptor class B type I (SR-BI) receptor (6, 7) in a mechanism 
that is aided by the secreted enzyme hepatic lipase (HL) (8), as will be 
discussed in greater detail. As such, mice lacking expression of either SR-BI 
or HL have elevated levels of HDL-C and impaired HDL-C clearance by 
hepatocytes (5, 9-12).  
 
Insulin resistance is a harbinger of type 2 diabetes and is pathogenetically 
linked to increased risk cardiovascular disease (CVD) (13, 14). Type 2 
diabetes is associated with a 2 – 4-fold CVD risk, and heart attacks are a 
leading cause of death among individuals with T2D (15). In insulin resistant 
individuals, CVD has been linked to a defect in reverse cholesterol transport 






movement of excess cholesterol from peripheral tissues to the feces, via the 
liver (13, 14, 16, 17). In RCT, cholesterol is accepted by HDL particles in the 
peripheral tissues (including macrophage foam cells) and off-loaded into the 
liver. These HDL particles are then recycled into the circulation to continue 
RCT. By depleting cholesterol, RCT has been shown to be cardioprotective 
(18).  
 
One potential linkage between insulin resistance and the development of 
CVD is the liver, a crucial organ that mediates both glucose and cholesterol 
metabolism (19-21). Therefore, it is feasible to hypothesize that a signaling 
defect in the liver, due to insulin resistance or hyperinsulinemia, could 
dysregulate the liver’s ability to remove excess cholesterol from the plasma 
via RCT. This could, in turn, cause a malfunction in HDL-C turnover during 
RCT, which may contribute to the buildup of atherosclerotic plaques, and 
subsequent CVD. However, while insulin resistance is characterized by a 
dysregulation in hepatic insulin signaling, the predisposing factors and 
mechanisms by which insulin resistance impairs RCT and accelerates CVD 
are unclear. 
 
This work tests the hypothesis that hepatic insulin signaling regulates HDL-C 
clearance. As prior work has established that hepatic FoxOs are required for 






levels, this work demonstrates that hepatic FoxOs are also required for 
proper expression of two genes involved in HDL-C clearance by the liver, 
namely Scarb1 (which encodes SR-BI) and Lipc (which encodes HL). 
Moreover, this work also proposes that the regulation of HDL-C uptake by 
FoxOs is part of a larger program of regulation of HDL-mediated RCT by 
hepatic insulin signaling. Taken together, this thesis seeks to uncover a 
novel mechanism by which RCT, a key mechanism of lipid homeostasis in 
vivo, is regulated by the hepatic insulinàFoxO signaling pathway. 
 
1.2. Insulin Signaling and Hepatic FoxOs 
1.2.1. The Insulin Signaling Pathway 
Under normal conditions, insulin acts by binding to insulin receptor, which is 
localized on the plasma membrane of target cells. The insulin receptor is a 
disulphide-bridged, heterodimeric receptor tyrosine kinase, comprising of 
two extracellular α subunits, and two integral membrane β subunits (22). 
Upon insulin binding, the insulin receptor undergoes a conformational 
change that initiates cross-phosphorylation of the receptor’s two 
cytoplasmic, tyrosine-kinase domains (23). This tyrosine phosphorylation in 
turn recruits the insulin receptor substrate (IRS) proteins, IRS1 and IRS2, 
which then become tyrosine phosphorylated by the insulin receptor (24). 
Phosphotyrosine sites on IRS1/2 allow the binding of phosphoinositol-3-






within IRS1/2, is able to phosphorylate glycolipid phosphatidylinositol-4,5-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5- triphosphate (PIP3) at the 
plasma membrane (25, 26). When PIP3 is synthesized in close proximity to 
the insulin-receptor/IRS complex, it allows the recruitment of protein kinase 
B (also known as AKT) (27). Once AKT is bound to PIP3 at the plasma 
membrane, it is then activated by 3-phosphoinositide-dependent kinase-1 
(PDK1), which directly phosphorylates the threonine 308 residue of AKT 
(28). A second phosphorylation at the serine 473 residue of AKT is also 
carried out by mTOR complex 2 (mTORC2) (29-31).  
 
Once activated, AKT phosphorylates a number of proteins at 
serine/threonine residues, many of which mediate the effects of insulin on 
glucose production, utilization and uptake, as well as the synthesis of 
glycogen, protein and lipid (3). These include the FoxO proteins, FoxO1, 
FoxO3, and FoxO4, which are a widely expressed class of transcription 
factors characterized by their forkhead DNA-binding domain (32, 33). In 
hepatocytes, FoxO1 is the most abundant and well-studied FoxO 
transcription factor (34, 35), although all three hepatic FoxOs have been 
shown to function additively to promote expression of their target genes 
(36). Following insulin signaling, AKT phosphorylates FoxO1 at three 
residues, threonine 24, serine 256, and serine 319, which causes its rapid 






(34, 37). During fasting, hepatic FoxOs shuttle back into the nucleus, where 
they bind to conserved recognition motifs located in the promoter regions of 
their target genes (also known as insulin response elements) (19, 35, 38-
40).  
 
1.2.2. Hepatic FoxO Regulation of G6pc and Gck 
Both skeletal muscle and adipose tissue require insulin signaling to directly 
stimulate glucose uptake via GLUT4 glucose transporter subcellular 
localization to the cell surface (41). In contrast, the liver utilizes GLUT2, a 
glucose transporter that allows the bidirectional flux of glucose in and out of 
hepatocytes and the bloodstream (42).  Moreover, unlike GLUT4, GLUT2 
mediated glucose transport is not directly induced by insulin signaling. 
Rather, glucose uptake in hepatocytes depends on the levels of hepatic 
glucose-6-phosphate (G6P), a phosphorylated form of glucose whose levels 
are mediated by two counterregulatory enzymes: (1) glucokinase (GCK, 
encoded by Gck), which phosphorylates glucose into G6P thereby promoting 
hepatic glucose uptake and utilization via glycogenesis or glycolysis, and (2) 
glucose-6-phosphatase (G6Pase, encoded by G6pc), which dephosphorylates 
G6P into free glucose thereby allowing glucose to be released into the 







Hepatic FoxOs are believed to promote hepatic glucose production in part by 
activating transcription of G6pc (45, 46). Indeed, mice with either adenoviral 
overexpression of wild-type FoxO1 (47) or transgenic expression of a 
constitutively active, insulin-insensitive mutant FoxO1 in liver (35, 48) were 
observed to have glucose intolerance, consistent with hyperglycemia and 
increased hepatic G6pc expression. Furthermore, mice with a liver-specific 
deletion of either IRS1/2 (40) or AKT1/2 (39) – factors upstream of hepatic 
FoxOs in the insulin signaling pathway – were also observed to have glucose 
intolerance, consistent with hyperglycemia and increased hepatic G6pc 
expression. In both liver-specific IRS1/2 and AKT1/2 knockout mice, this 
impairment could be completely reversed by concomitant liver-specific 
deletion of FoxO1 (39, 40).  
 
Conversely, the opposite phenotypes were observed in liver-specific FoxO1 
knockout (L-FoxO1) mice. L-FoxO1 mice exhibited improved glucose 
tolerance, consistent with decreased hepatic G6pc expression (49). 
Moreover, concomitant deletion of all three hepatic FoxOs (L-FoxO1,3,4) 
resulted in improved glucose tolerance beyond that of L-FoxO1 mice, 
although L-FoxO1,3,4 mice did not display further decreases in hepatic G6pc 
expression. Taken together, the data suggest that FoxO1 may preferentially 
regulate G6pc, whereas other targets that contribute to glucose and/or lipid 






Gck may be one such factor regulated by hepatic FoxOs in a redundant 
manner (21, 36). Gck was slightly elevated in L-FoxO1 mice livers when 
compared to that of littermate control livers, but was induced 3-fold in L-
FoxO1,3,4 mice livers, suggesting a synergistic or additive function of 
hepatic FoxO isoforms (36). Previously, insulin regulation of hepatic Gck was 
believed due to regulation by sterol regulatory element binding protein-1c 
(SREBP-1c) (50, 51). While the exact mechanism by which insulin regulates 
hepatic Gck was unclear (52), the pivotal discovery by Haeusler, R.A., et al. 
established the hypothesis that hepatic FoxOs, and not SREBP-1c, repress 
Gck expression (48, 53-55). In fact, liver-specific AKT1/2 knockout mice 
were observed to have nearly undetectable levels of GCK protein expression, 
which was partially rescued by concomitant FoxO1 knockout (39). Feasibly, 
partial GCK rescue in this model was due to compensation by intact FoxO3 
and FoxO4, and thus concomitant knockout of all 3 hepatic FoxOs might 
result in complete GCK rescue.   
 
Gck phosphorylates glucose into G6P, which, through a series of enzymatic 
reactions, can be catabolized into acetyl-CoA, the principal building block 
utilized in de novo lipogenesis (DNL) (56). As such, increased Gck is 
expected to increase DNL (57-59). In L-FoxO1,3,4 mice, DNL rates were two 
to three times higher than that of control mice in both fasted and refed 






increased expression of the of target genes of canonical lipogenic 
transcription factors Srebp-1c and Chrebp, including Acaca, Fasn, Elovl6 
and Pklr (21). Instead, the underlying mechanism explaining the increased 
DNL appears to be the rapid increase in Gck expression (independent of 
feeding state), coupled with decreased G6pc expression in the absence of 
hepatic FoxOs (21). Taken together, the data suggest that the G6pc:Gck 
ratio reflects the direction of glucose flux; thus, in the absence of hepatic 
FoxOs, the G6pc:Gck ratio is decreased, thereby resulting in increased flux 
through glycolysis and DNL, independent of feeding state (21).  
 
According to the “Bifurcation model”, proposed by Brown and Goldstein in 
2008, insulin regulation of glucose and lipid metabolism are parallel 
pathways mediated by FoxOs and SREBP-1c, respectively (60). The new 
model by Haeusler, R.A., et al. proposes that insulin instead acts on FoxOs 
and SREBP-1c sequentially; first, at low levels and early time points through 
FoxOs to reduce hepatic glucose production and initiate postprandial DNL by 
reducing the G6pc/Gck ratio; and second, at high levels and late time points 
through SREBP-1c to amplify DNL (21). This model is supported by the fact 
that FoxOs are inactivated within seconds of exposure to physiologic insulin 
doses, whereas SREBP-1c activation requires hours and higher insulin doses 
(3, 21, 61). Consequently, integrating both glucose production and 






FoxO activity plays a “rate-limiting” role in determining the direction of 
glucose flux. 
 
1.3. Cholesterol Metabolism 
1.3.1. Significance of Reverse Cholesterol Transport 
RCT is a multi-step process that results in the net movement of cholesterol 
from peripheral tissues to the feces, via the liver (13, 16, 17). A critical 
mediator of RCT is HDL. Circulating HDL particles accept excess cholesterol 
from peripheral tissues, including macrophage foam cells. Two major fates 
for this HDL-cholesterol (HDL-C) are (1) direct uptake into the liver by 
scavenger receptor class B, type I (SR-BI), or (2) transfer to LDL particles as 
a result of the activity of cholesteryl ester transfer protein (CETP), with 
subsequent uptake into the liver by LDL receptors (17). The ability to 
deplete cholesterol from foam cells is thought to be a major way in which 
HDL is cardioprotective (62).  
 
The strong inverse association of plasma HDL-C levels with CVD risk found in 
human epidemiological studies led to the development of the 'HDL 
cholesterol hypothesis', which posits that interventions to raise plasma HDL-
C would result in reduced CVD (18). Studies done in both humans and mice 
support this hypothesis, showing that increasing the plasma concentration of 






cholesterol efflux, effectively promotes RCT and prevents or reverses 
atherosclerosis (63, 64). However, recent clinical trials involving moderate 
therapeutic elevations of plasma HDL-C levels on individuals with low levels 
of plasma LDL-C failed to show any evidence of reduction in CVD (65, 66). 
Moreover, a recent Mendelian randomization study suggested that genetic 
variants causing changes in plasma HDL-C levels had a weak or nonexistent 
relationship with CVD risk, especially when these variants had no association 
with plasma LDL or triglyceride levels (67). Collectively, these studies 
indicate that plasma HDL-C levels may be a risk marker and not a causal 
risk mediator, thereby challenging the expectation that raising plasma HDL-
C levels per se and regardless of mechanism will reduce CVD risk (18).  
 
An alternative approach has been proposed: to promote HDL-mediated 
cholesterol efflux either (1) from macrophage foam cells to the circulation or 
(2) from the circulation into the liver and feces (62, 68). As such, the classic 
‘HDL-cholesterol hypothesis’ has been revised to the ‘HDL flux hypothesis’, 
which posits that an intervention to promote cholesterol efflux and RCT will 
reduce CVD risk (18, 69). With the HDL flux hypothesis in mind, we 
investigated how an insulin signaling pathway in hepatic FoxOs regulates 








1.3.2. SR-BI  
The HDL receptor, SR-BI, plays a crucial role in RCT, lipoprotein metabolism, 
and CVD prevention. The sequence was first isolated and identified in 1993, 
and was originally named CLA-1 (70). It wasn’t until 1996 that SR-BI was 
demonstrated to bind to HDL with high affinity and mediate the selective 
uptake of HDL cholesteryl ester (CE), defined as lipid internalization 
independent of holo-particle uptake (7). While selective uptake is the 
primary method by which HDL-C is taken up by SR-BI, SR-BI can also 
mediate the bidirectional flux of free cholesterol between cells and HDL (71, 
72). In addition to the liver, SR-BI is also expressed in steroidogenic cells 
such as gonadal tissues and adrenal gland, endothelium, macrophages, 
adipocytes, and platelets (73, 74). 
  
The structure and stability of SR-BI is important, especially when considering 
SR-BI as a therapeutic target for CVD prevention. SR-BI is a hairpin-looped 
structure with two short transmembrane domains, two cytoplasmic tails, and 
a large extracellular loop (75). In order for selective uptake of CE to occur, 
HDL is required to bind to the subdomains of the C-terminal half of the 
extracellular domain (76). SR-BI contains a large cavity that spans the 
entire length of the receptor, and mutagenesis studies revealed that the 
cavity acts as a lipophilic “tunnel” through which CE is delivered from the 






SR-BI forms oligomers at the C-terminal region of the extracellular domain, 
and CE transport is proportional to the degree of oligomerization (78, 79). 
The C-terminal cytoplasmic domain contains a PDZ-binding domain that 
interacts with adaptor protein, PDZK1, and in hepatocytes, PDZK1 maintains 
steady state levels of SR-BI by preventing its degradation (80). 
 
Numerous factors have been implicated in the transcriptional regulation of 
Scarb1, the gene encoding SR-BI. Among these include several 
heterodimeric nuclear receptors, including peroxisome proliferator-activated 
receptors (PPARs), liver X receptors (LXRs), and pregnane X receptor (PXR) 
(81). PPARs are ligand-activated transcription factors that heterodimerize 
with RXR to regulate gene expression (82). Among the PPAR receptors, 
activation of PPARa and PPARg have been shown to positively regulate SR-BI 
gene transcription (81). Indeed, in hamsters treated with diets enriched with 
polyunsaturated fatty acids (a strong inductor of PPARa), both SR-BI mRNA 
and protein expression are increased, which correlate with higher transfer of 
HDL-C to the liver and lower plasma HDL-C levels (83). Likewise, treatment 
with selective PPARg agonists induces SR-BI transcription in rat hepatocytes, 
endothelial cells, and Kupffer cells by a mechanism involving co-activation of 
HNF4a (84). Regarding the LXR receptors, LXRa and LXRb, activation of both 






murine cell lines, but this has not been demonstrated in vivo (85). Moreover, 
oxysterols also induce the rate-limiting bile acid biosynthesis enzyme, 
cholesterol 7a-hydroxylase (CYP7A1), thereby stimulating cholesterol 
excretion in bile and increasing overall bile acid bioavailability (85). In 
contrast to PPARs and LXRs, activation of the nuclear receptor, PXR, appears 
to negatively regulate SR-BI gene expression (81). In vitro PXR agonism in 
hepatocytes represses SR-BI mRNA synthesis (86), and in vivo PXR agonism 
increases HDL levels, partially due to a decrease in hepatic SR-BI levels (81, 
87, 88). 
 
Additional nuclear receptors have also been reported to modulate SR-BI 
gene transcription, namely the liver receptor homolog-1 (LRH-1) and 
estrogen receptors. In vitro, LRH-1 induces SR-BI promoter activity in 
hepatocytes (89), and in vivo, partial deficiency of LRH-1 is associated with 
decreased hepatic SR-BI expression in mice (90). The estrogen receptor has 
also been implicated in modulating SR-BI gene transcription. Upon binding 
to their cytoplasmic-specific nuclear receptors, estrogens are translocated to 
the nucleus, where they regulate the transcriptional activity of SR-BI (91, 
92). In vivo, treatment of rats with synthetic estrogen 17a-ethynilestradiol 
promotes a decrease in SR-BI expression in hepatocytes, associated with an 
increase in SR-BI expression in Kupffer cells (93). Interestingly, this 






pituitary-derived secondary factors, as hypophysectomy prevents the 
estrogen-mediated effects on SR-BI gene expression (94). 
 
In addition to receptor-mediated regulation, hepatic expression of SR-BI is 
also regulated transcriptionally through signaling pathways involving 
endogenous compounds, including insulin-like growth factors (95), glucose 
(96), proinflammatory agents (97), leptin (98), vitamin A (99), as well as 
some synthetic compounds such as pratensein and trichostatin (100-102), 
all of which are neither primary nor direct activators of transcriptional factors 
(81). Of note, the adipokine leptin is a key regulator of energy 
intake/expenditure that positively regulates the expression of hepatic SR-BI 
at both mRNA and protein levels (98, 103). Indeed, in both leptin deficient 
(ob/ob) and leptin receptor deficient (db/db) animal models, plasma HDL-C 
levels are increased, consistent with decreased hepatic SR-BI expression 
(98). While these results may suggest that obese patients with leptin-
mediated pathway defects have increased CVD risk due to impaired hepatic 
SR-BI-mediated HDL-C clearance, there is no definitive evidence 
demonstrating that leptin levels directly modulate HDL metabolism and SR-
BI expression in humans (81). Interestingly, the neuronal melanocortin 
system, which is downstream of the leptin signaling, is also an endogenous 
regulator of SR-BI expression, as inhibition of melanocortin signaling in the 






mechanisms increases circulating HDL-C via reduction in hepatic SR-BI 
expression (104). 
 
Extensive studies done in animal models have demonstrated the importance 
of SR-BI in preventing the development of CVD. SR-BI mediates the last 
step in RCT, that is, the removal of HDL-CE and free cholesterol from the 
periphery for biliary excretion. As such, SR-BI knockout mice have increased 
plasma cholesterol consisting primarily of large HDL (5). Moreover, SR-BI 
knockout mice fed a western-type diet (WTD) for 20 weeks develop 
significantly more atherosclerosis compared to wild-type mice (105). 
Concomitant deletion of SR-BI in apoE knockout mice consuming a chow diet 
causes accelerated atherosclerosis resulting in coronary artery occlusion, 
myocardial infarction, and premature death at 5-8 weeks of age (75, 106, 
107). These mice present with severe hypercholesterolemia (~1000mg/dl), 
consisting of very large HDL particles in the size range of LDL and VLDL 
particles (75, 107, 108). It has been suggested that the accelerated 
atherosclerosis is in part due to their abnormal lipoprotein profile (108, 109). 
These results are consistent with another study done in WTD-fed SR-
BI/LDLR double knockout mice, which have an abnormal lipoprotein profiles 
along with more severe coronary atherosclerosis, myocardial infarction and 






Taken together, these studies challenge the conventional ‘HDL-cholesterol 
hypothesis’ from human epidemiology that elevated HDL-C is 
cardioprotective, but rather provide in vivo support that promoting 
cholesterol efflux and RCT will reduce CVD risk (i.e. the ‘HDL flux 
hypothesis’) (74). Indeed, hepatic SR-BI overexpression promotes HDL 
clearance by the liver, thereby reducing circulating HDL-C levels and 
atherosclerosis in atherosclerosis-susceptible mouse models (4, 74, 110-
115). 
 
In addition to studies done in animal models, common variants at the 
SCARB1 locus in humans have also been studied for their relationship to 
plasma lipid and CVD development. Two recent studies have identified two 
different rare nonsynonymous variants in SCARB1 (i.e. P297S, P376L) that 
cause elevated HDL-C in the form of enlarged, apoE-enriched particles (116, 
117). In mice, these variants cause a loss of CE transport function in SR-BI 
(74, 75).  
 
In the P297S study, one out of 162 unrelated individuals with HDL-C levels 
greater than the 95th percentile was found to carry the P297S variant in 
SCARB1 (116). The study followed up with an additional 18 family members 
carrying the variant, and found that, relative to non-carrier family controls, 






consistent with enlarged, apoE-enriched HDL particles (74, 116). P297S was 
also associated with impairments in carrier-derived macrophage cholesterol 
efflux to HDL, platelet aggregation, and adrenal steroidogenesis, but was not 
associated with CVD risk (74, 116).  
 
In the P376L study, 328 participants with HDL-C levels greater than the 95th 
percentile were screened and one homozygote and four heterozygotes were 
found to carry the P376L variant (117). These individuals with the P376L 
variant had elevated HDL-C and HDL size, but interestingly the HDL was not 
apo-E enriched (117). Moreover, there was no notable CVD in this small 
sample size. However, when a very large consortium spanning multiple 
cohorts of CVD cases and controls was genotyped for the P376L variant 
(n=137,995 individuals), the authors found that P376L carriers had a 
significantly higher risk of CVD compared with non-carriers (albeit a 
moderate association, odds ratio = 1.79, P = 0.018) (74, 117). While this 
study identified the first homozygote for a loss of function variant in SCARB1 
in humans, and supports the notion that raising HDL-C via SCARB1 
inactivation is proatherogenic, the extremely low and variable carrier rate of 
the mutation between study groups (overall 86 carriers in 137,995) raised 
the possibility that the P376L variant may be an indirect marker for a 
substratum of the population (118, 119). In fact, a very recent study done in 






mutations (G319V, V111M, and V32M, combined allelic frequency = 0.2%) 
associated with elevated HDL-C levels comparable to that reported for 
P376L, but no associated CVD risk (odds ratio = 0.90, P = 0.49) (119). The 
authors of Icelandic study argued that, while it is conceivable the mutation 
encoding P376L has CVD susceptibility effects that are not shared by other 
HDL-C raising variants of SCARB1, it is more likely that differences in 
population substructure between cases and controls is the main explanation 
of the reported association of P376L with CAD (119). This is especially 
apparent given that the P376L variant is relatively specific to Ashkenazi Jews 
(119). Thus, further investigation will be required to determine the extent to 
which SR-BI deficiency in humans impairs atheroprotective HDL signaling 
responses, and to what extent this may contribute to CVD development 
(118). 
 
1.3.3. Hepatic Lipase 
HL is a liver-secreted enzyme that is one of three members of the 
triglyceride lipase family (along with lipoprotein lipase and endothelial lipase) 
that contributes to vascular lipoprotein degradation (120). HL hydrolyzes 
triglycerides and phospholipids, and is involved in processing large lipid-rich 
HDL to smaller HDL (8, 121). As such, mice that lack HL have increased 
plasma concentrations of HDL-C and phospholipids (12). In addition, HL’s 






lipoproteins and lipoprotein lipids with hepatic cell surface receptors or 
proteoglycans (122-127). This includes facilitating hepatic HDL-CE uptake 
via SR-BI (128, 129). Taken together, these functions suggest that HL plays 
a cardioprotective role by aiding in hepatic HDL-CE clearance thereby 
increasing overall RCT.  
 
HL is synthesized in the endoplasmic reticulum, and consists of a 
glycoprotein with four N-linked oligosaccharide side chains (130). Following 
secretion, HL is bound to heparin sulfate proteoglycans on the surface of 
hepatocytes (130). Interestingly, HL acquires its lipase activity intracellulary, 
and can influence the formation of luminal lipid droplets and the secretion of 
VLDL (131, 132). Indeed, increased presence of active HL in the ER 
compartment in hepatoma cells depleted TG stores, attenuated VLDL 
secretion and increased FA oxidation (133). These findings raise the 
possibility that increasing HL activity could be beneficial for mitigating liver 
triglyceride accumulation (132). Thus, further investigation will be required 
to determine whether HL is suitable for pharmacologic intervention.  
 
Several reports have demonstrated that Lipc can be transcriptionally 
regulated by other factors (134-137). The human LIPC promoter is reported 
to be activated by hepatocyte nuclear factor 4a (HNF4a), along with 






coactivator that moderately stimulates HNF4a-mediated transactivation 
(134). This HNF4a/PGC-1a activation of the LIPC promoter can be blocked 
by apolipoprotein A-I regulatory protein-1 (ARP-1) through competitive 
inhibition of the HNF4a binding site (134). Additionally, hepatocyte nuclear 
factor 1a (HNF1a) also independently activates the LIPC promoter using its 
own HNF1 binding site (134). In HepG2 cells, glucose reportedly increases 
Lipc expression via elevation of upstream stimulatory factors 1 and 2 
(USF1/USF2) (135). Moreover, oleic acid also increases Lipc expression in 
hepG2 cells via USF1 (136). Finally, the estrogen receptor a (and 
consequently the estrous cycle) has been reported to repress Lipc gene 
transcription (137, 138).   
 
In humans, genetic variants in LIPC have been described that cause HL 
deficiency and associated hyperlipidemia, namely the S267F and T383M 
variants (139). Moreover, four promoter polymorphisms of LIPC in linkage 
disequilibrium have also been identified (140, 141). Of the four, the G-250A 
polymorphism in the promoter region of the LIPC has been found to be 
associated with changes in plasma lipid concentrations (142-149) and the 
risk of CVD (150-155) in some studies, but not in others (156-159). 
Moreover, in certain subpopulations, the LIPC variants appear to increase 






particularly in type 2 diabetics (153, 163), suggesting that HL may play a 
role in the development of both type 2 diabetes and CVD. Interestingly, 
hepatic lipase inactivation in an insulin resistant mouse model (apoE-/-Irs2+/-
HL-/-) decreased atherosclerosis, consistent with reduced inflammation and 
macrophage proliferation (164). This study suggests that HL modulates an 
inflammatory pathway in the setting of insulin resistance, and thus plays a 
role in CVD development (164). Taken together, these studies warrant 
further investigation in order to understand the mechanisms by which HL 




The cholesterol ester transfer protein (CETP) is a circulating enzyme that 
catalyzes the transfer of CE from HDLs to apoB-containing lipoproteins; in 
exchange, HDLs acquire triglycerides from LDL, VLDL, and chylomicrons, 
thereby leading to a net depletion of the HDL cholesterol core and a parallel 
enrichment of CE in apoB-containing lipoproteins (74, 165, 166). 
Consequently, this enzyme allows an alternative pathway by which HDL-C 
can be cleared via the LDL receptor. While mice naturally lack CETP, several 
studies done in CETP transgenic/overexpression mice have shown that CETP 
expression can decrease circulating HDL-C levels and increase overall RCT 






atherosclerosis in some mouse models (169, 170). Interestingly, in SR-BI 
deficient mice, CETP expression in mice promotes RCT (171) and protects 
against diet induced atherosclerosis (170).   
 
In humans, CETP variants have a strong association with HDL-C levels (172-
175). Whether genetic variants in CETP also influence the risk of CVD, 
however, is unclear (74). In a large GWAS study, a common variant at the 
CETP locus has been robustly associated with decreased HDL-C, but 
nominally associated with increased CHD risk (172). Two recent studies 
assessed whether one CETP variant, rs708272, which is strongly associated 
with increased HDL-C, is also associated with decreased CVD risk. The 
studies had inconsistent results, indicating no CVD association in one (176), 
and reduced CVD in the other (74, 177). Another recent case-control study 
demonstrated for the first time that loss of function coding mutations in 
CETP that raise HDL-C are associated with reduced CVD risk (178), whereas 
a previous study has shown increased CVD risk in people with CETP 
deficiency (179). Taken together, these studies raise the question whether 
whereas a previous study has shown increased CVD risk in people with CETP 
deficiency raising HDL-C via CETP inhibition can reduce CVD risk. Indeed, 
several small molecule CETP inhibitors have been developed over the years, 
with most of them failing to demonstrate a significant improvement in 






doubling HDL-C (66, 74, 180, 181). More recently, one CETP inhibitor, 
anacetrapib, significantly reduced cardiovascular events in subjects with 
vascular disease treated with a statin (182). However, the reduction in CVD 
risk was mild (~9%), and was also associated with reduced LDL-C, making it 
difficult to determine whether the drug’s HDL-C raising effects were causal of 
the reduced CVD risk (74). Consequently, evidence thus far have failed to 
demonstrate clear results that the mechanism by which CETP raises HDL-C is 
cardioprotective, thereby supporting the paradigm that promotion of RCT is 
more imperative for reducing CVD risk. 
 
1.4. Hypothesis and Specific Aims  
While the hypothesis has been proposed that insulin resistance and type 2 
diabetes leads to alterations in HDL-C metabolism and RCT (13), many of 
the underlying mechanisms are still not well understood. As discussed at 
length above, hepatic FoxOs play an essential role in regulating both glucose 
and triglyceride metabolism. Hepatic FoxOs have also been shown to 
regulate other lipid-regulatory pathways, including bile acid metabolism 
(183-187). Here, we hypothesize that hepatic FoxOs can also regulate HDL-






aims to further our understanding of the hepatic insulinàFoxO signaling 
pathway, and its ability to influence CVD risk through alterations in RCT.   
 
In Chapter 2, we demonstrate that in L-FoxO1,3,4 mice have increased HDL-
C, associated with decreased expression SR-BI and HL, and defective 
selective uptake of HDL-CE by the liver. Our findings demonstrate that the 
insulinàFoxO signaling pathway can modulate HDL-C levels. This concept is 
supported by evidence collected as part of other unrelated studies (40, 48, 
188). Indeed, IRS1/2 double knockout mice have decreased HDL-C levels 
(40), presumably due to increased hepatic FoxO activity. As such, 
concomitant deletion of hepatic FoxO1 partially rescues HDL-C levels, but 
not to levels of that of control mice (40). It is likely that HDL-C was not 
completely normalized to normal levels by FoxO1 deletion due to 
compensation by intact FoxO3 and FoxO4. Consistent with this mouse 
model, liver insulin receptor knockout (LIRKO) mice was shown to have a 
50% decrease in HDL-C (188). Finally, gene-array studies revealed that 
Scarb1 is upregulated in FoxO1 transgenic mice (48). Taken together, these  
studies support our model by which hepatic FoxOs are required for 
cholesterol homeostasis and HDL-mediated RCT to the liver. 
In Chapter 3, we test our model that hepatic FoxOs influence RCT by 
measuring macrophage-to-feces RCT in L-FoxO1,3,4 mice. Furthermore, we 






hepatic FoxO regulation of HDL-C metabolism and RCT. First, we 
characterize L-FoxO1,3,4 mice expressing a human CETP transgene (L-
FoxO1,3,4:CETPtg) in order to understand the contribution of CETP to RCT in 
the setting of hepatic FoxO ablation. Second, we observe sex-specific 
differences in L-FoxO1,3,4 mice, suggesting that that sex may play a role in 
the degree of HDL-C clearance and overall RCT in the setting of hepatic FoxO 
ablation. Finally, in Chapter 4, we discuss our findings in Chapter 3, 
including potential pitfalls and possibilities of our results. We also integrate 
the information discussed throughout this thesis and formulate potential 
future directions that will (i) improve our understanding of the relationships 
between insulin resistance, diabetes, and atherogenesis, and (ii) inform 
distribution of cholesterol with respect to lipoprotein fractions clinical  


















The liver is a critical site for maintaining metabolic homeostasis. In 
hepatocytes, the forkhead transcription factors of the FoxO sub-family, 
FoxO1, FoxO3, and FoxO4 (FoxOs), mediate a substantial portion of insulin-
regulated gene transcription (19, 35, 38-40). During fasting, FoxOs are 
active, whereas insulin signaling suppresses FoxO activity via Akt-mediated 
phosphorylation and nuclear exclusion (34, 37). The three FoxOs work in 
concert to promote expression of their target genes (36). Previously, we 
have demonstrated that liver-specific ablation of these three hepatic FoxOs 
in mice prevents the induction of glucose-6-phosphatase and the repression 
of glucokinase during fasting, thereby increasing lipogenesis at the expense 
of glucose production (21). FoxOs are also required for expression of 
multiple other genes involved in liver metabolic pathways (48, 183, 189). 
These findings demonstrate that hepatic FoxOs play a vital role in 
maintaining proper glucose and lipid homeostasis. 
 
The liver also plays an essential role in cholesterol metabolism. One 
important aspect is to facilitate the clearance of cholesterol from circulating 
high-density lipoprotein (HDL) particles into the liver, where it can be 
converted to bile acids or transported directly into the bile to be excreted in 
the feces (4, 5). HDL-cholesterol (HDL-C) is primarily cleared by scavenger 






selective HDL-cholesteryl ester (CE) uptake, defined as lipid internalization 
independent of holo-particle uptake (6, 7). Acting alongside SR-BI is the 
enzyme, hepatic lipase (HL) (8). Studies show that (a) HL is a liver-secreted 
enzyme that hydrolyzes triglycerides and phospholipids and is involved in 
processing large lipid-rich HDL into smaller HDL particles (121), and (b) HL’s 
ligand-binding activity may mediate interactions of lipoproteins with SR-BI or 
the plasma membrane, thus facilitating selective HDL-CE uptake (122-127). 
As such, mice lacking expression of either SR-BI or HL have elevated levels 
of HDL-C and impaired HDL-C clearance by hepatocytes (5, 9-12). 
 
In the current study, we utilized mice with liver-specific ablation of three 
hepatic FoxOs (L-FoxO1,3,4) (21, 36) and littermate controls with the 
genotype Foxo1flox/flox, Foxo3flox/flox, and Foxo4flox/Y, to explore the role of 
hepatic FoxOs in regulating HDL-C metabolism. We observed that L-
FoxO1,3,4 mice have an increase in plasma HDL-C, especially when 
challenged with a western-type diet (WTD). Moreover, we also found that 
hepatic FoxOs are required for the expression of HDL-C clearance factors, 
SR-BI and HL, suggesting that selective HDL-CE uptake by the liver may be 
diminished in L-FoxO1,3,4 mice. In order to directly measure selective HDL-
CE clearance, metabolic studies were performed using HDL that was 
radiolabeled in both the protein (125I) and the lipid ([3H]) moieties. We found 






in vivo as well as in isolated L-FoxO1,3,4 primary murine hepatocytes in 
vitro. Moreover, the accumulation of HDL-C in L-FoxO1,3,4 mice was 
attenuated by rescue of SR-BI expression. Thus, our data indicate that the 
increase in plasma HDL-C in L-FoxO1,3,4 mice is primarily a consequence of 
reduced HDL lipid uptake by the liver. These findings suggest that, in 
addition to the established effects on glucose and triglyceride metabolism, 
hepatic FoxOs are required for HDL-mediated reverse cholesterol transport, 
a key mechanism of lipid homeostasis in vivo. 
 
2.2. Results  
2.2.1. Deletion of Hepatic FoxOs Increases Cholesterol Accumulation 
in Large HDL Particles. 
We first measured plasma cholesterol in chow-fed mice, and found 50% 
higher plasma cholesterol in L-FoxO1,3,4 mice compared to littermate 
controls (Figure 2.1A). In order to determine the distribution of cholesterol 
with respect to lipoprotein fractions, we separated the plasma by fast protein 
liquid chromatography (FPLC). We found that chow-fed L-FoxO1,3,4 mice 
had increased HDL-C and accumulation of cholesterol in the fractions that 
elute similarly to large HDL (Figure 2.1B). We performed western blot 
analysis of these fractions and found that apoA-I, the major apolipoprotein 
of HDL, is shifted to the left, indicating larger HDL particles. We also found a 






established characteristics of large, spherical HDL particles (190, 191). In 
contrast, apoB-containing particles eluted much earlier, peaking at fraction 
47-49 (Supplemental Figure S2.1A) and disappearing by fraction 52, 
indicating that there is little to no difference in LDL-C between genotypes. 
There were no differences in total plasma apoA-I (Supplemental Figure 
S2.1B), suggesting that the leftward shift of apoA-I, apoE, and HDL-C 
indicates the presence of larger HDL particles in L-FoxO1,3,4 mice. There 
were also no differences in total plasma triglycerides between genotypes 
(data not shown). 
 
Next, we challenged the mice with a western-type diet (WTD) consisting of 
21% milkfat and 0.2% cholesterol. The WTD is known to increase plasma 
cholesterol levels and to induce atherogenesis in susceptible strains (192). 
After three weeks of WTD feeding, L-FoxO1,3,4 mice showed 65% higher 
plasma cholesterol compared to WTD-fed controls (Figure 2.1D). The 
cholesterol profile in the knockouts was exacerbated on this diet, showing 
accumulation of cholesterol in fractions that elute similarly to large HDL 
(Figure 2.1E). Consistent with this, there was a leftward shift in apoA-I 
(Figure 2.1F). There was also abundant accumulation of apoE in these 
shifted fractions, similar to what is seen in other experimental mouse models 






total plasma apoA-I (Supplemental Figure S2.1B). These data support the 
hypothesis that hepatic FoxOs play a role in HDL-C metabolism. 
 
2.2.2. FoxOs are Required for Expression of Scavenger Receptor  
SR-BI and Hepatic Lipase  
To identify contributors to the accumulation of plasma HDL-C in L-FoxO1,3,4 
mice, we queried microarrays from livers of L-FoxO1,3,4 mice (21) for genes 
involved in HDL synthesis and clearance (Table 2.1). We found no 
differences in genes regulating HDL synthesis or biliary excretion, including 
Abca1, Apoa1, Apoa2, Lcat, Apoe, Abcg5, and Abcg8. We also found no 
significant differences in Apoc3, Srebp2, Hmgcr, or Pltp. However, L-
FoxO1,3,4 mice showed reduced expression of two genes involved in HDL-C 
clearance: Scarb1 (which encodes SR-BI) and Lipc (which encodes HL). 
Using quantitative PCR, we verified that L-FoxO1,3,4 mice showed significant 
reductions in Scarb1 and Lipc during both chow and WTD feeding (Figure 
2.2A-B). We also verified that there were no differences in Abca1, Apoa1, 
Apoa2, Apoc3, Apoe, Lcat, Srebp2, Hmgcr, Abcg5, or Abcg8. By qPCR, there 
was an increase in Pltp expression, however increased Pltp alone is 
insufficient to increase HDL-C (194). These data suggest that the increase in 







We next confirmed that these decreases in Scarb1 and Lipc mRNA result in 
decreases at the protein level. By western blot, we found that in both chow-
fed and WTD-fed mice, SR-BI protein levels decreased significantly (>85%) 
in liver lysates isolated from L-FoxO1,3,4 mice compared to those of control 
mice (Figure 2.2C). Consistent with what was observed from the gene 
expression data, we found no changes in liver ABCA1 protein levels between 
L-FoxO1,3,4 and control mice fed either chow or WTD (Supplemental Figure 
S2.2).	To investigate HL, we measured its activity in non-heparinized plasma 
(195, 196). Compared to controls, L-FoxO1,3,4 mice had a 50% decrease in 
HL activity (Figure 2.2D). Taken together, these data demonstrate that 
hepatic FoxOs are required for normal expression of both SR-BI and HL. 
 
2.2.3. HDL Metabolism in L-FoxO1,3,4 and Control Mice 
To address HDL metabolism in more detail, we investigated the turnover of 
125I-tyramine cellobiose-WT-HDL and [3H]cholesteryl hexadecyl ether-WT-
HDL (125I-TC-/[3H]CEt-WT-HDL) in control and L-FoxO1,3,4 mice on chow 
(Figures 2.3-2.4) and WTD (Supplemental Figure S2.3-S2.4). We injected 
this murine HDL preparation intravenously in mice, and thereafter, we 
harvested blood samples periodically over a 24-hour period (6). In these 
studies, [3H]CEt traces the clearance of HDL-associated CE, and 125I-TC 
traces the clearance of HDL holo-particles (197). The difference between 






particles. In control mice on chow, the plasma decay of HDL-associated 
[3H]CEt was faster compared to 125I-TC (Figure 2.3A), indicating selective CE 
removal from the HDL plasma pool by tissues. In L-FoxO1,3,4 mice on chow, 
the plasma decay of 125I-TC was similar to control mice (Figure 2.3B). 
However, removal of HDL-associated [3H]CEt from plasma was slower in L-
FoxO1,3,4 mice compared to controls. Similarly, selective CE removal from 
the HDL plasma pool was also slower in WTD-fed L-FoxO1,3,4 mice 
compared to littermate controls (Supplemental Figure S2.3A-B). Thus, 
selective CE removal from HDL was markedly reduced in both chow-fed and 
WTD-fed L-FoxO1,3,4 mice. These results suggest that selective CE removal 
from the HDL plasma pool is substantially reduced in mice lacking hepatic 
FoxOs. 
 
From decay curves shown in Figure 2.3A-B and Supplemental Figure S2.3A-
B, we calculated the plasma-fractional catabolic rate (FCR) for both HDL-
associated tracers on chow (Figure 2.4A) and WTD (Supplemental Figure 
S2.4A) (198). In control mice, the plasma-FCR for HDL-associated [3H]CEt 
was substantially higher compared to 125I-TC due to selective CE removal 
from plasma by tissues. In chow-fed L-FoxO1,3,4 mice, we detected no 
significant difference in plasma-FCR for 125I-TC compared to control mice, 
although in WTD-fed L-FoxO1,3,4 mice, there was a slight decrease in 125I-






with control mice, we observed a significant reduction in the plasma FCR for 
[3H]CEt (p=0.0046 and p=0.031 for chow and WTD, respectively), yielding 
a significantly reduced rate of selective CE removal from plasma in             
L-FoxO1,3,4 mice (p=0.0001 and p=0.046 for chow and WTD, respectively). 
This shows that there is reduced selective CE clearance from the plasma HDL 
pool by tissues in L-FoxO1,3,4 mice.  
 
Next, we investigated HDL metabolism by defined organs. 24-hours after 
125I-TC-/[3H]CEt-WT-HDL injection, we analyzed tracer content of tissues, 
and calculated HDL uptake in terms of organ-FCR (6). In control mice on 
both diets, the hepatic organ-FCR showed selective CE uptake by the liver 
from HDL (Figure 2.4B and Supplemental Figure S2.4B) that was in line with 
earlier studies in wild-type mice (10, 199). In L-FoxO1,3,4 mice on both 
diets, the hepatic uptake rate for 125I-TC was similar to control mice. 
However, the hepatic organ FCR for [3H]CEt (p=0.0035 and p=0.011 for 
chow and WTD, respectively) and the selective CE uptake from HDL 
(p=0.0009 and 0.009 for chow and WTD, respectively) were decreased 
significantly compared with control mice on either diet. This indicates that 
hepatic selective uptake of HDL-CE is defective in L-FoxO1,3,4 mice. 
 
Compared with the liver, the HDL tracer uptake rates were quantitatively low 






chow-fed L-FoxO1,3,4 mice showed a trend towards reduced selective CE 
uptake (Figure 2.4C). However, this trend was not detected in WTD-fed L-
FoxO1,3,4 mice (Supplemental Figure S2.4C). We did not expect SR-BI 
expression to be lower in L-FoxO1,3,4 adrenals, because this is a 
hepatocyte-specific FoxO knockout mouse model. Indeed, there was no 
change in both Scarb1 and Foxo1 gene expression in L-FoxO1,3,4 adrenals 
(Supplemental Figure S2.5). However, because HL is a secreted protein that 
is known to function in SR-BI–mediated uptake of HDL-C, we speculate that 
the low HL activity of L-FoxO1,3,4 mice could potentially contribute to the 
trend of lower selective CE uptake in other SR-BI–expressing tissues (such 
as adrenal gland), in chow-diet conditions. In the kidneys, which do not 
express SR-BI, organ-FCR’s for both HDL-associated tracers did not differ 
between control and L-FoxO1,3,4 mice on either chow or WTD (Figure 2.4D 
and Supplemental Figure S2.4D). However, consistent with previous studies, 
kidney organ-FCRs for HDL-associated 125I-TC were higher compared to 
HDL-associated [3H]CEt, which reflects a preferential renal catabolism of 
HDL apolipoproteins (10). In spleen, stomach, intestine and carcass, the 
organ-FCR’s for HDL-associated [3H]CEt were decreased in chow-fed L-
FoxO1,3,4 mice compared to controls (Table 2.2). Of these tissues, only the 








2.2.4. HDL Metabolism in Primary Murine Hepatocytes 
Next, we investigated HDL-CE uptake into isolated primary hepatocytes from 
control and L-FoxO1,3,4 mice in a dose-response manner. Following a 4-hr 
seeding period, we incubated hepatocytes in medium containing 125I-TC-
/[3H]CEt-WT-HDL at 10, 20, 40 or 100 µg HDL protein/ml for 2-hrs. In 
control hepatocytes, [3H]CEt uptake is substantially higher than 125I-TC at all 
doses, indicating selective CE uptake from HDL (Figure 2.5A). This 
observation is in line with previous results (10, 200). In L-FoxO1,3,4 
hepatocytes, 125I-TC uptake was similar to controls (Figure 2.5B). However, 
[3H]CEt uptake was significantly decreased compared to control cells at all 
doses, yielding a ~50% decrease in selective CE uptake from HDL. We also 
measured HDL-CE uptake over a 2-hr time course at 20 µg HDL protein/ml 
(Supplemental Figure S2.6A-B). At all time points, selective HDL-CE uptake 
was significantly reduced by approximately 40 % in L-FoxO1,3,4 
hepatocytes compared to controls. Western blot analysis confirmed that SR-
BI protein levels are substantially decreased in L-FoxO1,3,4 hepatocytes 
compared to controls (Figure 2.5C). We also observed significantly lower 
expression of Scarb1 and Lipc mRNA from L-FoxO1,3,4 hepatocytes (Figure 
2.5D). However, we noted that the mRNA of both genes declined over time 
after hepatocyte isolation, especially in wild-type hepatocytes, as was 






that selective CE uptake from HDL is decreased in FoxO-deficient 
hepatocytes in a cell autonomous manner.  
 
2.2.5. Rescuing SR-BI Reverses the Accumulation of HDL-C in L-
FoxO1,3,4 mice 
 
To determine whether SR-BI induction in the livers of FoxO-deficient mice 
can reverse the HDL-C phenotype, we transduced WTD-fed L-FoxO1,3,4 
mice and littermate controls with an adenovirus expressing SR-BI (Ad.SR-
BI). We titrated the virus to a low-dose to achieve only mild increases in SR-
BI, because several-fold overexpression in wild-type mice is known to 
potently reduce HDL-C irrespective of the HDL subclass (4). Three days after 
virus injection, we measured SR-BI expression levels. As a result of the low 
titer we used, there were no increases in total SR-BI levels in control mice 
transduced with Ad.SR-BI compared to those transduced with a control virus 
(Ad.GFP) (Figure 2.6A). However, L-FoxO1,3,4 mice injected with Ad.SR-BI 
showed a five-fold increase in liver SR-BI compared to those injected with 
Ad.GFP. We noted that even after this 5-fold increase, the levels of SR-BI 
were still about half as much as those in littermate control mice. Transducing 
L-FoxO1,3,4 mice with SR-BI caused a substantial normalization of the HDL-
C accumulation (Figure 2.6B). Western blots confirmed that the leftward 
shifts of apoA-I and apoE were also normalized (compare lanes 10-11 with 






mice transduced with this low-titer Ad.SR-BI showed no overexpression of 
SR-BI, there was no decrease of HDL-C in these mice. Neither Lipc mRNA 
expression nor plasma HL activity was affected by Ad.SR-BI transduction 
(Supplemental Figure S2.7A-B). Collectively, these findings demonstrate 
that rescuing SR-BI expression in hepatic FoxO-deficient mice is sufficient to 
reverse the accumulation of cholesterol in large HDL particles. 
 
2.2.6. Acute Depletion of Hepatic FoxOs is Sufficient to Induce HDL 
Phenotype  
We predicted that Scarb1 and Lipc are transcriptional targets of FoxOs, 
because (i) the mRNA expression of these genes is low in every condition 
tested, (ii) motif analysis using HOMER (202) identified dozens of FoxO 
consensus sequences in and near Scarb1 and Lipc (Supplemental Figure 
S2.8A-C), and (iii) publicly available microarrays are consistent with this, 
showing that transgenic overexpression of constitutively active FoxOs causes 
elevated liver expression of Scarb1 mRNA (48). Moreover, mice lacking the 
insulin receptor substrate proteins (Irs1 and Irs2) – which are expected to 
have constitutively active FoxOs – have elevated liver expression of Scarb1 
and reduced serum HDL-C. Importantly, concomitant knockout of FoxO1 







To further validate that decreases in Scarb1 and Lipc are directly due to 
FoxO depletion, and not compensatory defects due to long-term genetic loss 
of FoxOs, we transduced chow-fed, adult Foxo1flox/flox, Foxo3flox/flox, and 
Foxo4flox/Y control mice with an adeno-associated virus expressing Cre under 
a hepatocyte-specific promoter (AAV8.Tbg.Cre). Two weeks after the 
injection, we found that chow-fed triple-floxed mice transduced with 
AAV8.Tbg.Cre virus started to accumulate cholesterol in large HDL fractions 
(Supplemental Figure S2.9). Four weeks after virus injection, we euthanized 
the mice. At that time point, the HDL-C accumulation phenotype was 
exacerbated compared to the two–week time point (Figure 2.7A). We 
verified that AAV8.Tbg.Cre caused FoxO depletion, as well as low levels of 
G6pc and high levels of Gck, two known targets of FoxO transcriptional 
activation and repression, respectively (21) (Figure 2.7B). Moreover, it 
caused decreases in Scarb1 and Lipc mRNA levels, as well as SR-BI protein 
levels (Figure 2.7C). The levels of Scarb1 and Lipc mRNA were significantly 
correlated with the level of FoxO1 knockdown (Figure 2.7D).  
 
Finally, we also measured protein expression levels of PDZK1 in L-FoxO1,3,4 
liver lysates and primary hepatocytes. PDZK1 is a scaffold protein that is 
essential for SR-BI stability and localization in hepatocytes, and has been 
reported to post-transcriptionally regulate SR-BI levels (203, 204). We found 






changes in PDZK1 expression levels between L-FoxO1,3,4 and matched 
controls. (Supplemental Figure S2.10). Thus we have no evidence for 
posttranslational regulation of SR-BI by FoxOs. Taken together, these data 
support a model whereby FoxOs acutely regulate Scarb1 and Lipc at the 




Here we report that hepatic FoxOs are required for normal hepatic clearance 
of HDL-C. Our results suggest that hepatic FoxOs promote the expression of 
SR-BI and HL, which induce HDL-C uptake from the plasma into the liver. 
This novel mechanism demonstrates the importance of these insulin-
inactivated transcription factors in regulating HDL-C metabolism. 
 
SR-BI and HL are both important for plasma HDL-C turnover. Both SR-BI 
and HL knockout mice have elevated plasma cholesterol levels and 
cholesterol accumulation in large HDL particles (5, 12) due to impaired 
selective uptake of HDL-CE by the liver (10, 11). Some studies have 
suggested that SR-BI and HL promote selective uptake by acting together 
(129), although others indicate that the two act through independent 
mechanisms (127). Evidence in humans also shows important roles for SR-






variants near both Scarb1 and Lipc have been associated with HDL-C (117, 
205, 206). Furthermore, individuals with HL deficiency were reported to 
have an accumulation of large, buoyant plasma HDL particles (207-209). 
Thus, mechanisms regulating HDL-C clearance through these two proteins 
may be relevant across species.  
 
Hepatic FoxOs have also been shown to control other downstream aspects of 
hepatic cholesterol metabolism. Once HDL-CE enters the hepatocyte, it can 
be stored, secreted on lipoproteins, or excreted into the bile. There are two 
possible mechanisms to allow for cholesterol excretion into the bile. The first 
is to be secreted directly into the bile via the heterodimeric cholesterol 
transporters Abcg5 and Abcg8 (210, 211). The second is to be converted 
into bile acids through a series of enzymatic reactions, in which Cyp7a1 
encodes the rate-limiting enzyme (212, 213). All three genes – Abcg5, 
Abcg8, and Cyp7a1 – are reportedly regulated by hepatic FoxO1 (184-187). 
Moreover, we have previously reported that an additional enzyme involved 
in bile acid synthesis, Cyp8b1, is a FoxO1 target (183). Our current findings 
that hepatic FoxOs also regulate clearance of HDL-C by the liver indicate 
that FoxOs have pleiotropic effects on hepatic cholesterol homeostasis.  
 
The inactivation of hepatic FoxOs by insulin signaling has been well 






that ablating the upstream FoxO regulators involved in this insulin signaling 
cascade (e.g. the insulin receptor, insulin receptor substrate proteins, or 
Akt) leads to impaired glucose homeostasis due to constitutive FoxO 
activation (39, 40, 49, 188). Thus, these models may also provide insight 
into the regulation of HDL-C levels via the insulin-FoxO pathway. For 
instance, liver ablation of the insulin receptor causes decreased serum HDL-
C associated with a reduction in large, apoE containing HDL particles (188). 
Likewise, Irs1 and Irs2 double-knockout mice have elevated Scarb1 mRNA 
levels and reduced serum HDL-C, whereas concomitant knockout of FoxO1 
with Irs1 and Irs2 partially reverses this (40). Furthermore, transgenic 
overexpression of constitutively active FoxOs increases liver Scarb1 mRNA 
(48). These data provide additional evidence to suggest that hepatic FoxOs 
directly mediate insulin’s effect on HDL-C metabolism through their 
transcriptional effects on Scarb1 and Lipc.  
 
We propose that the regulation of HDL-C uptake by FoxOs is part of a larger 
program of hepatic insulin regulation of cholesterol metabolism.  In addition 
to what is uncovered in the present work, liver insulin signaling is also 
known to positively regulate the Srebp2 pathway (188) and the levels of the 
LDL receptor (214), and negatively regulate the catabolism of cholesterol 
into bile acids (215), biliary cholesterol excretion (184), and bile acid 






metabolism are regulated by nutrient status in order to coordinate (i) the 
supply of cellular membrane components, and (ii) the usage of available 
precursor molecules (216). As insulin is a key regulator of the nutrient-rich 
state, it is possible that its actions coordinate glucose, fatty acid, and 
cholesterol flux to maintain overall energy homeostasis.  
 
Given FoxOs’ well-known role in promoting hepatic glucose production (45), 
our findings suggest a potential connection between plasma glucose and 
plasma HDL-C in the setting of type 2 diabetes. Patients with type 2 diabetes 
have elevated plasma glucose, along with reduced plasma HDL-C (217). As 
excessive FoxO activity is expected to contribute to high hepatic glucose 
production in these patients (45), perhaps it also contributes to their low 
HDL-C. Indeed, one of the FoxO targets we identified–HL–is known to have 
increased activity in type 2 diabetes patients (218, 219). Hence, it is 
possible that elevated FoxO activity in the setting of type 2 diabetes leads to 
more rapid HDL-C turnover.  
 
It is of interest that L-FoxO1,3,4 mice accumulate cholesterol preferentially 
in large, apoE rich HDL particles, while the amount of cholesterol on 
“traditional” sized HDL remains unchanged between genotypes. It has been 
reported that apoE facilitates the uptake of HDL-CE via SR-BI in vivo (220). 






222). Thus it is possible that these preferences of SR-BI and HL may 
contribute to the specific accumulation of apoE-containing HDL in L-
FoxO1,3,4 mice. Another observation we noted was that the difference in 
HDL-C between genotypes was exacerbated on the WTD, despite the fact 
that HL is halved and SR-BI is exceedingly low in L-FoxO1,3,4 mice on both 
diets. What is the cause of this HDL-C exacerbation? Interestingly, SR-BI 
knockout mice also show the same exacerbation: differences in HDL-C 
between SR-BI knockout mice and controls are greater after western diet 
feeding than chow diet feeding (105). Thus the exacerbation is independent 
of additional SR-BI lowering. We speculate that multiple factors may be 
involved, including changes on the particles themselves. Some of these may 
include alterations in other HDL lipid species or HDL-bound proteins, or 
potential increased competition for clearance of apoE-rich HDL particles via 
the alternative pathway of LDLR/LRP1/HSPGs (in other words, western-diet 
induced increases in apoB-containing particles may compete with apoE-rich 
HDL for binding to LDLR/LRP1/HSPG).  
 
In this work, we have demonstrated a novel link between the insulin-
repressible FoxO transcription factors and HDL-mediated reverse cholesterol 
transport. This cardioprotective pathway is a critical step for the excretion of 
cholesterol from the periphery to the feces (16-18, 62). Indeed, patients 






significantly increased levels of plasma HDL-C as well as an increased risk of 
coronary heart disease (117). Thus, further characterization of how the 
insulin-FoxO pathway regulates reverse cholesterol transport may (i) 
improve our understanding of the relationships between insulin resistance, 
diabetes, and atherogenesis, and (ii) inform clinical decisions about future 
treatments for diabetes-related cardiovascular disease. 
 
2.4. Materials and Methods 
2.4.1. Mice and Diets 
Only adult male mice, 3-5 months old, were studied. L-FoxO1,3,4 mice have 
been previously described (21, 36). Control mice represent Foxo1flox/flox, 
Foxo3flox/flox, and Foxo4flox/Y mice that lack the liver-specific α1-antitrypsin-
cre. Mice were fed either standard chow diet (Purina), or WTD containing 
42% kcal from fat and 0.2% cholesterol (TD 88137, Harlan Teklad) for 3 
weeks. For the adenovirus experiments, mice were injected intravenously 
with 1 x 108 virus particles/gram of body weight 3 days prior to sacrifice. 
Murine SR-BI adenovirus was a gift from Dr. Charles M. Rice (223). For the 
acute FoxO depletion experiments, mice were injected intravenously with 1 x 
1011 virus particles/mouse 4 weeks prior to sacrifice. AAV8.Tbg.Cre was a 
gift from Dr. Morris Birnbaum (Perelman School of Medicine – University of 
Pennsylvania, Philadelphia, Pennsylvania USA). Mice were fasted for 5-hrs on 






are housed in a 12-hr light/dark cycle, with the dark cycle occurring between 
7:00 p.m. and 7:00 a.m.  
 
2.4.2. Plasma Lipoprotein Analysis 
Total plasma cholesterol was measured using a commercial colorimetric 
assay (Wako). Plasma lipoproteins were analyzed by running 200 µl of 
pooled plasma onto a FPLC system consisting of two Superose 6 columns 
connected in series (Amersham Pharmacia Biotech) as described (224). 
Fractions for chow-fed mice were collected using fraction collector FC 204 
(Gilson), and fractions for WTD-fed mice were collected using fraction 
collector FRAC-100 (Pharmacia LKB). For western blots of fractionated 
plasma in both chow-fed and WTD-fed mice, 5 µl from each fraction were 
pooled in pairs, and were run on a 4%-15% Tris-HCL gradient gel (Bio-Rad), 
with the exception of adenovirus-injected mice, for which 5µl from each 
fraction were pooled in groups of 4 or 6, as indicated in figure 2.6. 
Antibodies to apoA-I and apoE were from Meridian Life Science (catalogs 
K23500R and K23100R, respectively). 
 
2.4.3. Gene Expression 
Liver RNA was isolated using TRIzol (Invitrogen). cDNA was synthesized 






Green (New England Biolabs). Genes were normalized to 36b4. Primer 
sequences are available in supplemental experimental procedures.  
 
2.4.4. SR-BI expression and HL activity 
Liver lysates were prepared in T-PER tissue extraction buffer (ThermoFisher) 
with added protease inhibitor cocktail (Roche), and immunoblotted for SR-BI 
(Novus – NB400-104), and beta-Actin (13E5, Cell Signaling – 4970S) as 
loading control. For western blots of SR-BI in primary hepatocytes, cells 
were isolated and incubated as described (20). Plasma HL activity was 
determined as described (195). Briefly, plasma was incubated with 10% 
Intralipid/[3H]-triolein (Perkin Elmer – NET431L005MC) emulsion as 
substrate, and human serum as the source of apoCII (225). The contribution 
of hepatic lipase in the plasma was determined by including NaCl (final 
concentration 1M) (226). Because heparin was not administered to mice 
prior to blood collection, the lipase activity was primarily HL (196). 
 
2.4.5. Radiolabeling of HDL 
HDL was prepared from wild-type (WT) mice that were fasted 4-hrs before 
blood harvest. Murine WT-HDL (density = 1.063-1.21 g/ml) was isolated 
from plasma by sequential ultracentrifugation (227). Murine WT-HDL was 
double labeled with 125I-tyramine cellobiose (125I-TC) in the apolipoprotein 






NET859001MC) in the CE moiety (10, 228). [3H]CEt was introduced in 125I-
TC-WT-HDL by exchange from donor liposomal particles, which contained 
[3H]CEt using human plasma cholesteryl ester transfer protein (229).The 
final 125I-TC-/[3H]CEt-WT-HDL preparation was extensively dialyzed against 
PBS (pH 7.4, 4°C) containing EDTA (1 mM).  
 
2.4.6. HDL Metabolism in Mice 
For plasma decay analysis of radiolabeled WT-HDL, mice were fasted for 4-
hrs before tracer injection (6).	Then, 125I-TC–/[3H]CEt-WT-HDL (30 µg 
protein/mouse) was injected via the tail vein, and thereafter, blood samples 
(30 µl/time point) were collected periodically (10 minutes, 30 minutes, 2 
hours, 7 hours, 22 hours, and 24 hours) after injection. Animals were fasted 
throughout the 24-hr study period but had unlimited access to water. 
Plasma aliquots were directly assayed for 125I radioactivity and [3H] was 
analyzed after lipid extraction (230). Computer modeling was used to fit (by 
method of least squares) multiexponential curves, arising from a common 
two-pool model, simultaneously to both tracers’ plasma decay data, and to 
calculate plasma fractional catabolic rates (plasma-FCR’s) for each tracer 
(231). The modeling was done separately for the data from each mouse, so 








Tissue sites of uptake of HDL-associated tracers were determined 24-hrs 
after injection of radiolabeled WT-HDL (6). Finally, animals were deeply 
anesthetized, the abdomen and chest were opened, and a catheter was 
inserted into the right heart. The inferior vena cava was cut, and the mice 
were perfused extensively with saline (50 ml per animal). After perfusion, 
liver, adrenals, kidneys, heart, lungs, spleen, stomach, intestine and carcass 
from each mouse were harvested and homogenized. Homogenates from 
each tissue and from carcass were directly assayed for 125I radioactivity, and 
aliquots were analyzed in parallel for [3H] after lipid extraction (230). 
 
Total radioactivity recovered from all tissues and from the carcass of each 
mouse was calculated (6). The fraction of total tracer uptake attributed to a 
specific organ was calculated as the radioactivity recovered in that organ 
divided by the total radioactivity recovered from all tissues and carcass. 
Thus the % of recovered extravascular radioactivity in tissues is determined 
24-hrs after injection of labeled HDL.  
 
To allow comparison of the specific activities of various tissues in HDL 
internalization and to directly compare the rates of uptake of the 
apolipoprotein component and the CE moiety of HDL, the data are expressed 
as organ fractional catabolic rates (organ-FCR’s) (6). These rates are 






[%] of total body tracer recovery in tissue X). This organ-FCR represents the 
fraction of the plasma pool of either HDL tracer cleared by an organ per 
hour. 125I-TC represents the uptake of HDL holo-particles by tissues (197). 
Selective HDL CE uptake is calculated as the difference in organ-FCR 
between [3H]CEt and 125I-TC.  
 
2.4.7. Preparation of Murine Hepatocytes 
Primary hepatocytes were isolated from murine liver by perfusion (37°C, 18 
min) with Hanks’ balanced salt solution supplemented with collagenase (0.3 
mg/ml, type I), HEPES (10 mM), and protease inhibitor mixture “complete” 
(232). Thereafter, these cells were seeded (37°C, 4.0-hr) in DMEM 
containing FBS (5%, v/v), penicillin (100 µg/ml) and streptomycin (100 
µg/ml). Finally, the culture medium was aspirated, and the cells were 
washed 3 times in PBS. Hepatocytes were used for 125I-TC-/[3H]CEt-WT-HDL 
uptake assays. For time course of gene expression in primary hepatocytes, 
we isolated RNA from hepatocytes at multiple time points during the 
isolation: (1) Directly after perfusion and before passing the cell suspension 
through a filter, (2) After the filter, (3) After washing cells, (4) 2-hr after 









2.4.8. Uptake Assay for Radiolabeled HDL with Hepatocytes 
To determine cellular uptake of radiolabeled HDL, hepatocytes incubated 
(37°C, 10, 30 or 120 minutes) in DMEM containing BSA (5 mg/ml), penicillin 
(100 µg/ml), streptomycin (100 µg/ml) and 125I-TC-/[3H]CEt-WT-HDL (200); 
the respective incubation time and the concentration of labeled HDL are 
given in the figure legends. Finally, cells were harvested by trypsin/EDTA (1 
x trypsin 0.05 %, EDTA 0.53 mM) treatment, and cellular uptake of HDL 
tracers was measured. 125I was directly radioassayed, and [3H] was analyzed 
after lipid extraction (230). Uptake of 125I-TC-/[3H]CEt-WT-HDL by cells is 
shown in terms of apparent HDL particle uptake, expressed as HDL protein 
(6, 200). This is done to compare the uptake of both tracers on a common 
basis. The uptake of HDL holo-particles is represented by 125I-TC, and the 
difference between [3H]CEt and 125I-TC yields apparent selective HDL CE 
uptake by cells (197). 
 
2.4.9. Motif Analysis 
To determine the number of potential FoxO binding motifs within or near the 
Scarb1 and Lipc sequences, we obtained the entire mouse gene sequences 
of Scarb1 and Lipc (including intronic regions), along with 50kb of sequence 
upstream of each gene’s transcription start site. Sequences were obtained 
from the UCSC Genome Browser (https://genome.ucsc.edu). The sequences 






EnRichment) (202) algorithm software, which provided the coordinates of all 
the potential FoxO binding motifs within this selected region. 
 
2.4.10. Primer Sequences  
Primer sequences for genes that were measured via qPCR. For liver and 
adrenal tissues, genes were normalized to 36b4. For primary hepatocytes, 
genes were normalized to B2m. 
Gene Direction Sequence (5'-3') 
36b4 Forward AGATGCAGCAGATCCGCAT 
36b4 Reverse GTTCTTGCCCATCAGCACC 
B2m Forward CTGGTGCTTGTCTCACTGAC 
B2m Reverse GTTCAGTATGTTCGGCTTCC 
Abca1  Forward GGTTTGGAGATGGTTATACAATAGTTGT 
Abca1  Reverse CCCGGAAACGCAAGTCC 
Abcg5 Forward TGGATCCAACACCTCTATGCTAAA 
Abcg5 Reverse GGCAGGTTTTCTCGATGAACTG 
Abcg8 Forward GTAGCTGATGCCGATGACAA 
Abcg8 Reverse GGGGCTGATGCAGATTCA 
Apoa1 Forward TGTGTATGTGGATGCGGTCA 
Apoa1 Reverse ATCCCAGAAGTCCCGAGTCA 
Apoc3 Forward GCATCTGCCCGAGCTGAAGAG 






Apoe Forward CCGGTGCTGTTGGTCACATTGCTGACAGGAT 
Apoe Reverse GTTCTTGTGTGACTTGGGAGCTCTGCAGCT 
Foxo1 Forward TCCAGTTCCTTCATTCTGCACT 
Foxo1 Reverse GCGTGCCCTACTTCAAGGATAA 
G6pc Forward GTCTGGATTCTACCTGCTAC 
G6pc Reverse AAAGACTTCTTGTGTGTCTGTC 
Gck Forward CTGTTAGCAGGATGGCAGCTT 
Gck Reverse TTTCCTGGAGAGATGCTGTGG 
Hmgcr Forward CTTGTGGAATGCCTTGTGATTG 
Hmgcr Reverse AGCCGAAGCAGCACATGAT 
Lcat Forward GCTGGCCTGGTAGAGGAGATG 
Lcat Reverse CCAAGGCTATGCCCAATGA 
Lipc Forward GACGGGAAGAACAAGATTGG 
lipc Reverse GGCATCATCAGGAGAAAGG 
Pltp Forward TGGGACGGTGTTGCTCAA 
Pltp Reverse CCCACGAGATCATCCACAGA 
Scarb1 Forward GGCTGCTGTTTGCTGCG 
Scarb1 Reverse GCTGCTTGATGAGGGAGGG 
Srebp2 Forward GATGATCACCCCGACGTTCAG 








CE, cholesteryl ester; FCR, fractional catabolic rate; FoxO, forkhead box 
class of transcription factors, family O (including FoxO1, FoxO3, and FoxO4); 
FPLC, fast protein liquid chromatography; HDL, high density lipoprotein; 
HDL-C, HDL-cholesterol; HL, hepatic lipase; L-FoxO1,3,4, liver-specific 
ablation of the three hepatic FoxOs; SR-BI, scavenger receptor class B type 
I; TC, tyramine cellobiose; WT, Wild-type; WTD, western-type diet 
 
2.4.12. Statistical Analyses 
Data are presented as mean ± SEM. Data were analyzed by two-tailed 
Student's t-tests, or one-way or two-way ANOVA followed by post-hoc test 
in R, as appropriate. Statistical tests used for each comparison are listed in 
the figure legends. P value < 0.05 was considered statistically significant. 
 
2.4.13. Study Approval 
All animal protocols were approved by the Institutional Animal Care and Use 
Committees of the University Hospital Hamburg and Columbia College of 


















































































































































































































Figure 2.1. Plasma Cholesterol Profiles of Chow-fed and WTD-fed L-FoxO1,3,4 Mice 
(A) Total plasma cholesterol in chow-fed L-FoxO1,3,4 mice and littermate controls after a 5-hr fast (n=5). 
Data are presented as mean ± SEM. (B) Cholesterol levels in plasma fractionated by FPLC in same 
mice as 1A. (C) Western blot of plasma apoA-I and apoE from pooled pairs of fractionated plasma 
obtained from FPLC in 1B. (D) Total plasma cholesterol in WTD-fed L-FoxO1,3,4 mice and littermate 
controls after a 5-hr fast (n=5). Data are presented as mean ± SEM. (E) Cholesterol levels in plasma 
fractionated by FPLC in same mice as 1D. (F) Western blot of plasma apoA-I and apoE from pooled 
pairs of fractionated plasma obtained from FPLC in 1E. Independent FPLC-cholesterol profiles for both 









































1.00 ± 0.16 	 0.92 ± 0.18 	 0.14 ± 0.08§§ 0.09 ± 0.03†† 
Figure 2.2. Defects in HDL Metabolism Genes Due to Ablation of Hepatic FoxOs  
(A-B) Relative hepatic gene expression by qPCR in (A) chow-fed L-FoxO1,3,4 mice and littermate 
controls (n=4-5), and in (B) WTD-fed L-FoxO1,3,4 mice and littermate controls (n=6-7). (C) 
Representative western blot of hepatic SR-BI expression in both chow-fed and WTD-fed L-FoxO1,3,4 
mice and littermate controls. SR-BI/Actin denotes relative SR-BI expression levels by densitometric 
scanning (n=4 per group total). (D) Relative plasma hepatic lipase activity in WTD-fed L-FoxO1,3,4 
mice and littermate controls (n=5-7). *p < 0.05, **p < 0.01, ****p < 0.0001; §§p < 0.01 between chow-
fed L-FoxO1,3,4 mice and littermate controls; ††p < 0.01 between WTD-fed L-FoxO1,3,4 mice and 



































































































x = 125I-TC 
O = [3H]CEt 
A 
Figure 2.3. Plasma Decay Kinetics of 125I-TC-/[3H]CEt-WT-HDL in Chow-Fed L-FoxO1,3,4 Mice  
(A-B) 125I-TC-/[3H]CEt-WT-HDL was injected intravenously in chow-fed L-FoxO1,3,4 mice and littermate 
controls. Thereafter, during a 24-hr interval, periodic blood samples were harvested and plasma was 
analyzed for 125I-TC (crosses) and [3H]CEt (circles). The y-axis represents the fraction of the tracer in 
plasma (%). Shown is a trace from a representative mouse from each genotype, with (A) control on the left 
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Figure 2.4. Plasma-FCRs and Tissue Tracer Uptake Rates for 125I-TC-/[3H]CEt-WT-HDL in Chow-
Fed L-FoxO1,3,4 Mice  
125I-TC-/[3H]CEt-WT-HDL was injected intravenously in chow-fed L-FoxO1,3,4 mice and littermate 
controls. (A) During the subsequent 24-hr interval, blood was harvested periodically to determine the 
plasma decay of both tracers. 125I-TC (125I) and [3H]CEt ([3H]) were analyzed, and plasma-FCRs for 
125I-TC and [3H]CEt were calculated. The difference in plasma-FCRs between [3H]CEt and 125I-TC was 
calculated. 24-hrs after tracer injection, the animals were euthanized, and tissues were analyzed for 
both tracers. (B) Liver, (C) adrenal and (D) kidney organ-FCRs for 125I-TC (125I), [3H]CEt ([3H]), and the 
difference in organ-FCRs between [3H]CEt and 125I-TC ([3H]CEt - 125I-TC) were calculated. All 
calculations were done as described in Materials and Methods. n = 7 control and n = 5 L-FoxO1,3,4 
mice. An independent experiment yielded qualitatively identical results. **p < 0.01, ***p < 0.001, ****p ≤	 
0.0001 by Student’s t-tests. In adrenal glands, there were no significant differences between 













Figure 2.5. Uptake of 125I-TC-/[3H]CEt-WT-HDL by Hepatocytes Isolated from Chow-Fed                    
L-FoxO1,3,4 Mice  
(A-B) Hepatocytes from chow-fed L-FoxO1,3,4 mice and littermate controls were incubated (37°C, 2.0-hr) 
in medium containing 125I-TC-/[3H]CEt-WT-HDL (10, 20, 40 or 100 µg HDL protein/ml). Finally, cells were 
harvested, and apparent HDL particle uptake was analyzed as outlined in Materials and Methods. Values 
are means of (A) n = 3 (control) or of (B) n = 3 (L-FoxO1,3,4) independent determinations. An 
independent similar experiment yielded qualitatively identical results. Where no error bars are visible, the 
SEM was smaller than the symbol. (C) Western blots of SR-BI in primary hepatocytes from L-FoxO1,3,4 
mice and littermate controls. Representative bands are shown. Two independent experiments yielded 
qualitatively identical results. (D) Relative Scarb1 and Lipc expression by qPCR in hepatocytes from 
chow-fed L-FoxO1,3,4 mice and littermate controls at different stages of the cell isolation procedure. See 
Materials and Methods. For (A-B): §§§p < 0.001, §§§§p < 0.0001 comparing [3H]CEt between                 
L-FoxO1,3,4 and control hepatocytes; ***p < 0.001, ****p < 0.0001 comparing [3H]CEt - 125I-TC between 
L-FoxO1,3,4 and control hepatocytes; †p < 0.05, ††p < 0.01 comparing 125I-TC between L-FoxO1,3,4 and 
control hepatocytes by Student’s t-tests. For (D): $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001 comparing 
gene expression between L-FoxO1,3,4 and control hepatocytes at each stage; #p < 0.05, ##p < 0.01, 
###p < 0.001, ####p < 0.0001 comparing gene expression between control hepatocytes at baseline (Pre-
Filter) and control hepatocytes at each stage; &&p < 0.01, &&&&p < 0.0001 comparing gene expression 
between L-FoxO1,3,4 hepatocytes at baseline (Pre-Filter) and L-FoxO1,3,4 hepatocytes at each stage. p 
values in (D) were calculated by two-way ANOVA, followed by post-hoc Tukey test, using the pooled 
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0.55 ± 0.05  1.00 ± 0.09  1.16 ± 0.09  0.11 ± 0.05  
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Figure 2.6. SR-BI Adenovirus in WTD-fed L-FoxO1,3,4 Mice 
(A) Western blot of hepatic SR-BI expression in WTD-fed L-FoxO1,3,4 mice and littermate controls 
transduced with Ad.SR-BI or control virus (Ad.GFP). SR-BI/Actin denotes relative SR-BI expression 
levels by densitometric scanning (n=2-4). (B) Cholesterol levels in plasma fractionated by FPLC in same 
mice as 6A. (C) Western blot of plasma apoA-I and apoE in fractionated plasma obtained from FPLC in 













AAV.GFP AAV8.Tbg.Cre Virus 



















































R2 = 0.88 





















R2 = 0.66 
P = 0.0007  
AAV.GFP AAV8.Tbg.Cre L-FoxO1,3,4 D 
Figure 2.7. Acute Knockdown via Cre Adeno-Associated virus in Chow-fed Hepatic FoxO Floxed Mice  
(A-D) Chow-fed, adult Foxo1flox/flox, Foxo3flox/flox, and Foxo4flox/Y control mice transduced with adeno-
associated virus (serotype 8) expressing Cre recombinase driven by the hepatocyte-specific Tbg promoter 
(AAV8.Tbg.Cre) or control virus (AAV.GFP) (n=5). For comparison, we also included a group of traditional     
L-FoxO1,3,4 knockout mice that were not transduced with virus, but rather had FoxO deficiency since birth 
(n=4). Four weeks after virus transduction, mice were fasted for 5-hrs and then plasma and livers were 
collected. (A) Cholesterol levels in plasma fractionated by FPLC 4 weeks after virus transduction. (B) Relative 
hepatic gene expression by qPCR. (C) Representative western blot of hepatic SR-BI expression. SR-BI/Actin 
denotes relative SR-BI expression levels by densitometric scanning. *p < 0.05, **p < 0.01 compared to 
AAV.GFP mice. Between AAV8.Tbg.Cre mice and L-FoxO1,3,4 mice, there was no significant difference.    
(D) Correlation between Scarb1 or Lipc mRNA with FoxO1 mRNA. p values in (B) and (C) were calculated by 
one-way ANOVA, followed by post-hoc t-test, using the pooled standard deviation, without Bonferroni 



































































































Supplemental Figure S2.1. Western Blot of “LDL” Fractions And Total Plasma apoA-I. Related to 
Figure 2.1. 
(A) Western blot of plasma apoB100, apoB48, apoA-I, and apoE from fractions 45-52 of fractionated 
plasma obtained from FPLC in 2.1B. FPLC from 2.1B is shown again here for reference. (B) Plasma was 
collected from chow-fed and WTD-fed L-FoxO1,3,4 mice and littermate controls. Plasma was diluted by 
1:200 with PBS, from which 20µl from each sample were run on a 4%-15% Tris-HCL gradient gel and 
blotted for apoA-I. Numbers denote relative apoA-I expression levels by densitometric scanning (n=4-7). 
Values are presented as mean ± SEM. Shown is a typical experiment. Independent experiments yielded 
qualitatively identical results.  
Control-Chow L-FoxO1,3,4-Chow 
apoA-I 
1.00 ± 0.13 	 1.31 ± 0.18 	
Control-WTD L-FoxO1,3,4-WTD 
apoA-I 














































































ABCA1/Actin 1.00 ± 0.32 	 0.93 ± 0.32 	 1.39 ± 0.19 1.69 ± 0.29 
Chow WTD 
SR-BI 
SR-BI/Actin 1.00 ± 0.17 	 1.35 ± 0.42 	 0.24 ± 0.07 0.38 ± 0.13 
Supplemental Figure S2.2. Western Blot of Liver ABCA1 and SR-BI from Chow-Fed and WTD-
Fed L-FoxO1,3,4 Mice. Related to Figure 2.2. 
Representative western blot of hepatic ABCA1 and SR-BI expression in both chow-fed and WTD-fed 
L-FoxO1,3,4 mice and littermate controls. ABCA1/Actin and SR-BI/Actin denote relative ABCA1 and 
SR-BI expression levels by densitometric scanning, respectively (n=4). ABCA1 antibody was 
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x = 125I-TC 
O = [3H]CEt 
10	 10	
Supplemental Figure S2.3. Plasma Decay Kinetics of 125I-TC-/[3H]CEt-WT-HDL in WTD-Fed L-
FoxO1,3,4 Mice. Related to Figure 2.3.  
(A-B) 125I-TC-/[3H]CEt-WT-HDL was injected intravenously in WTD-fed L-FoxO1,3,4 mice and littermate 
controls. Thereafter, during a 24-hr interval, periodic blood samples were harvested and plasma was 
analyzed for 125I-TC (crosses) and [3H]CEt (circles). The y-axis represents the fraction of the tracer in 
plasma (%). Shown is a trace from a representative mouse from each genotype, with (A) control on the left 
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Figure S2.4. Plasma-FCRs and Tissue Tracer Uptake Rates for 125I-TC-/[3H]CEt-WT-HDL in WTD-Fed                 
L-F xO1,3,4 Mice. Related to Figure 2.4. 
125I-TC-/[3H]CEt-WT-HDL was injected intravenously in WTD-fed L-FoxO ,3,4 mice and littermate controls. (A) During 
the subsequent 24-hr interval, blood was harvested periodically to determine the plasma decay of both tracers. 125I-TC 
(125I) and [3H]CEt ([3H]) were analyzed, and plasma-FCRs for 125I-TC and [3H]CEt were calculated. The difference in 
plasma-FCRs between [3H]CEt and 125I-TC was calculated. 24-hrs after tracer injection, the animals were euthanized, 
and tissues were analyzed for both tracers. (B) Liver, (C) adrenal and (D) kidney organ-FCRs for 125I-TC (125I), [3H]CEt 
([3H]), and the difference in organ-FCRs between [3H]CEt and 125I-TC ([3H]CEt - 125I-TC) were calculated. All 
calculations were done as described in Materials and Methods. n = 6 control and n = 5 L-FoxO1,3,4 mice. An 
independent similar experiment with n=5 control mice and n=4 L-FoxO1,3,4 mice yielded qualitatively identical results 
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Figure S2.5. Adrenal Gene Expression in Chow-Fed L-FoxO1,3,4 Mice. Related to Figure 2.4. 
Relative adrenal Scarb1 and Foxo1 gene expression by qPCR in chow-fed L-FoxO1,3,4 mice (n=3) 
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Figure S2.6. Kinetics of Uptake of 125I-TC-/[3H]CEt-WT-HDL by Hepatocytes Isolated from Chow-
Fed L-FoxO1,3,4 Mice. Related to Figure 2.5. 
(A-B) Hepatocytes from chow-fed L-FoxO1,3,4 mice and littermate controls were incubated (37°C, 10, 
30 or 120 minutes) in medium containing 125I-TC-/[3H]CEt-WT-HDL (20 µg HDL protein/ml). Finally, cells 
were harvested, and apparent HDL particle uptake was analyzed as outlined in Materials and Methods. 
Values are means of (A) n = 3 (control) or of (B) n = 3 (L-FoxO1,3,4) independent determinations. 
Shown is a typical experiment. An independent similar experiment yielded qualitatively identical results. 
§§ p < 0.01, §§§ p < 0.001 comparing [3H]CEt between L-FoxO1,3,4  and control hepatocytes; ** p < 
0.01, *** p < 0.001, **** p < 0.0001 comparing [3H]CEt - 125I-TC between L-FoxO1,3,4 and control 
hepatocytes by Student’s t-tests. Data are presented as mean ± SEM. Where no error bars are visible, 
the error was smaller than the symbol.  
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Figure S2.7. Effect of SR-BI Adenovirus on HL in WTD-fed L-FoxO1,3,4 Mice. Related to Figure 
2.6. 
(A) Relative hepatic Lipc expression by qPCR in WTD-fed L-FoxO1,3,4 mice and littermate controls 
transduced with Adeno.SR-BI or control virus (Adeno.GFP). (n=3-4). **p<0.01 by two-way ANOVA. (B) 























Scarb1	 59	 4	 16	 31	 =110		
Lipc	 174	 7	 14	 42	 =237	
Figure S8. Potential FoxO Binding Site Analysis of Scarb1 and Lipc Using HOMER Motif Discovery Algorithm  
(A) Summary of potential FoxO binding motifs near Scarb1 and Lipc. The entire sequences for mouse Scarb1 and 
Lipc, along with 50kb of sequence upstream of their respective transcription start sites were taken from the UCSC 
Genome Browser (https://genome.ucsc.edu). The sequences were analyzed by the HOMER algorithm software, which 
provided the coordinates of all the potential FoxO binding motifs within the selected regions. Values are grouped by 
motifs within the gene sequence, motifs from the transcription start site to 5kb upstream of start site, 5kb-20kb 
upstream of start site, 20kb-50kb upstream of start site, and total number of motifs. 
(B-C) Schematics from the UCSC Genome Browser highlighting positions of all motifs in selected region for (B) Scarb1 
and (C) Lipc. Highlighted in yellow are the relative coordinates of all potential FoxO binding motifs found though 
HOMER. Each motif is represented as a vertical line (“|”). Transcription start sites are indicated by the red arrow (both 
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Figure S2.9. Cholesterol Levels in Plasma Fractionated by FPLC in Chow-fed Hepatic FoxO Floxed 
Mice Transduced with Liver Specific Adeno-Associated Virus Expressing Cre. Related to Figure 2.7. 
Plasma was collected 2 weeks after virus transduction and fractionated by FPLC in chow-fed, adult control 
mice containing all three FoxO alleles floxed (Foxo1flox/flox, Foxo3flox/flox, and Foxo4flox/Y), and transduced with 























Figure S2.10. Western Blot of Liver PDZK1 from WTD-Fed L-FoxO1,3,4 Mice and Hepatocytes 
Isolated from L-FoxO1,3,4 mice. Related to Figure 2.7. 
(A-B) Representative western blot of hepatic PDZK1 expression from (A) WTD-fed L-FoxO1,3,4 mice 
and littermate controls in vivo, or (B) hepatocytes isolated from chow-fed L-FoxO1,3,4 mice and 















Table 2.1. L-FoxO1,3,4 Microarray From Liver Tissues 
Microarrays were performed from liver tissues of chow-fed L-FoxO1,3,4 mice 
and littermate controls (21). 
Gene	 Control	 L-FoxO1,3,4	 P	value	
Scarb1	 1	 0.727	 0.043	
Lipc	 1	 0.364	 0.00091	
Abca1	 1	 1.132	 0.27	
Apoa1	 1	 0.950	 0.17	
Apoa2	 1	 0.96	 0.56	
Apoc3	 1	 0.86	 0.28	
Apoe	 1	 0.951	 0.25	
Lcat	 1	 1.021	 0.86	
Srebp2	 1	 0.80	 0.47	
Hmgcr	 1	 0.473	 0.22	
Pltp	 1	 1.89	 0.11	
Abcg5	 1	 0.928	 0.76	
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64	 3.82±0.59	 0.32	±	0.022	 2.30	±	0.15*	 1.38	±	0.14*	
	 Stomach	 1.90±0.23	 1.27±0.24	
	 1.01±0.14*	 0.348±0.060*	 	
	 Intestine		 7.3±1.2	 4.0±0.52	 	 7.5±0.7	 2.5±0.27*	 	
	 Heart	 0.35±0.064	0.25±0.035	 	 0.32±0.013	 0.20±0.016	 	
	 Lungs	 0.55±0.11	 0.64±0.088	 	 0.57±0.059	 0.49±0.039	 	






















Table 2.2. Plasma-FCRs and Tracer Uptake Rates by Tissues for 125I-
TC-/[3H]CEt-WT-HDL in Chow-Fed L-FoxO1,3,4 mice 
125I-TC-/[3H]CEt-WT-HDL was injected intravenously in chow-fed L-
FoxO1,3,4 mice and littermate controls. During the subsequent 24-hr 
interval, blood was harvested periodically to determine the plasma decay of 
both tracers. 125I-TC (125I) and [3H]CEt ([3H]) were analyzed, and plasma-
FCRs for 125I-TC and [3H]CEt were calculated. The difference in plasma-FCRs 
between [3H]CEt and 125I-TC was calculated. 24-hrs after tracer injection, 
the animals were euthanized, and tissues were analyzed for both tracers.  
Spleen, stomach, intestine, heart, lungs and carcass organ-FCRs for 125I-TC 
(125I), [3H]CEt ([3H]), and the difference in organ-FCRs between [3H]CEt and 
125I-TC ([3H]CEt - 125I-TC) were calculated. All calculations were done as 
described in Materials and Methods. For all mice, values represent the mean 
± SEM. n = 7 control mice and n = 5 L-FoxO1,3,4 mice. An independent 






























3.1. Macrophage-to-Feces RCT in L-FoxO1,3,4 Mice 
3.1.1. Macrophage-to-Feces RCT in WTD- and Chow-Fed Mice 
From the studies done in Chapter 2, we determined that hepatic FoxOs are 
required for normal hepatic clearance of HDL-C primarily due to hepatic 
FoxOs’ role in promoting the expression of SR-BI and HL. Following up with 
these studies, we hypothesized that overall in vivo RCT would be attenuated 
in the absence of hepatic FoxO expression. To test this hypothesis, we 
performed macrophage RCT studies in L-FoxO1,3,4 mice by measuring net 
radiolabeled cholesterol excretion due to macrophage-to-feces RCT (63, 171, 
233). Briefly, J774 macrophages loaded with radiolabeled cholesterol 
([3H]cholesterol) were intraperitoneally injected in L-FoxO1,3,4 mice. 
Serum/Plasma and feces were collected over 48 hours, after which the mice 
were exsanguinated, harvested for tissues, and analyzed for tracer counts. 
On WTD, L-FoxO1,3,4 mice had increased macrophage-derived 
[3H]cholesterol in serum (Figure 3.1A, n=6,6), consistent with our hepatic 
clearance data shown in Chapter 2. However, there was no change in 
[3H]cholesterol levels in neither liver nor feces between WTD-fed L-FoxO1,3, 
4 mice and matched controls (Figure 3.1B-D).  
 
We repeated these studies with a larger cohort (n=9,12) in L-FoxO1,3,4 
mice and matched controls, and this time mice were fed chow instead of 






chow-fed L-FoxO1,3,4 mice and matched controls (Figure 3.2A). However, 
hepatic tracer counts were significantly lower in chow-fed L-FoxO1,3,4 mice 
(Figure 3.2B). In contrast to our expectations, we found increased fecal 
excretion of 3H-tracer in chow-fed L-FoxO1,3,4 mice compared to littermate 
controls (Figure 3.2C), which appeared to be due to increased neutral sterol 
excretion (Figure 3.2D). Thus our two experiments (one in WTD-fed mice, 
and one in chow-fed mice) gave different results, and were inconclusive as 
to whether L-FoxO1,3,4 mice have alterations in macrophage-to-feces RCT. 
 
3.1.2. Defective Intestinal Cholesterol Reabsorption in L-FoxO1,3,4 
Mice 
While we initially hypothesized that L-FoxO1,3,4 mice would have decreased 
overall RCT similar to what was reported in SR-BI knockout mice (233), we 
suspected that there could have been confounding variables in L-FoxO1,3,4 
mice due to differences in intestinal cholesterol reabsorption. Hepatic FoxOs 
reportedly promote the expression of Cyp7a1 and are required for the 
expression of Cyp8b1, two rate-limiting enzymes involved in the production 
and composition of bile acids (183, 185-187). Our lab has found that L-
FoxO1,3,4 mice have decreased Cyp7a1 and Cyp8b1 expression (Figure 
3.3A). This is associated with a decreased total bile acid pool size, and a 
particular decrease in 12α-hydroxylated (12α-OH) bile acids (Figure 3.3B). 






conjugates – are more hydrophobic than the non-12α-OH bile acid species – 
muricholic acids. Thus L-FoxO1,3,4 mice have a decrease in the 
hydrophobicity index (234).  
 
Intestinal cholesterol absorption is promoted most efficiently by 
hydrophobic, micelle-forming, bile acids (235, 236). Thus, L-FoxO1,3,4 mice 
are expected to have low intestinal cholesterol absorption, due to decreases 
in both total bile acid pool size and hydrophobicity. Consequently, it is 
possible that the reason that L-FoxO1,3,4 mice have no decrease – and 
possibly an increase – in fecal excretion of 3H-tracer is due to a confounding 
effect of hepatic FoxOs on bile acid metabolism and intestinal cholesterol 
reabsorption. This effect may mask or counterbalance the effect of hepatic 
FoxOs on hepatic HDL-C clearance, and thus neutralize any abnormalities in 
overall RCT. 
 
In order to control for differences in intestinal cholesterol reabsorption, we 
adjusted our macrophage-to-feces RCT studies to include daily 
administration of ezetimibe. Ezetimibe is a pharmacological inhibitor that 
effectively lowers plasma LDL-cholesterol in humans by targeting intestinal 
Niemann-Pick C1-Like 1 (NPC1L1), the transporter required for intestinal 
cholesterol absorption (237, 238). We hypothesized that inhibiting intestinal 






FoxO1,3,4 mice and controls, thereby unmasking the potential defect in 
macrophage-to-feces RCT. Furthermore, we predicted ezetimibe would have 
a greater effect on overall RCT in controls than in L-FoxO1,3,4 mice since L-
FoxO1,3,4 mice are expected to already have low intestinal cholesterol 
reabsorption. We first conducted a pilot study in which we gavaged C57BL/6 
mice with either ezetimibe suspended in methyl cellulose solution or vehicle 
(methyl cellulose solution alone) as described (239). Mice were 
intragastrically gavaged daily with 100 µl of ezetimibe solution (0.25mg of 
ezetimibe dissolved in 150 µl of DMSO, suspended in 8.33mL of 0.4% 
methyl cellulose) or methyl cellulose alone for 3 days. As expected, we 
found that 3 days of ezetimibe administration was sufficient to increase fecal 
cholesterol excretion and decrease plasma cholesterol levels. (Figure 3.4A-
B).  
 
Using this paradigm, we repeated our macrophage-to-feces RCT study in 
chow-fed L-FoxO1,3,4 mice and littermate controls given daily oral doses of 
ezetimibe. Mice were given a daily oral dose of either ezetimibe or vehicle 
for 3 days prior to IP injection of radiolabeled macrophages, and a 4th dose 
the morning of macrophage injection. The mice were given a final (5th) oral 
dose of ezetimibe 24 hours after injection, and were euthanized 48 hours 
after macrophage injection. In control mice, ezetimibe treatment appeared 






vehicle treated control mice (Figure 3.5A-B). While these data suggest that 
ezetimibe increases overall RCT in control mice, there was no change in fecal 
excretion of 3H-tracer between ezetimibe and vehicle treated control mice 
(Figure 3.5C-D). In L-FoxO1,3,4 mice, ezetimibe treatment did not decrease 
[3H]cholesterol levels in plasma or liver to the same degree as seen in 
control mice (Figure 3.5A-B). While this is consistent with our prediction that 
ezetimibe would have a greater effect on overall RCT in controls than in L-
FoxO1,3,4 mice, there was no change in fecal excretion of 3H-tracer between 
ezetimibe and vehicle treated L-FoxO1,3,4 mice (Figure 3.5C-D). Moreover, 
when comparing [3H]cholesterol levels between ezetimibe treated L-
FoxO1,3,4 and control mice, we saw no statistically significant change in 
plasma, liver, and feces (Figure 3.5A-D). Interestingly, there was also no 
change in plasma and liver [3H]cholesterol levels between vehicle treated L-
FoxO1,3,4 and control mice, which contradicts the decreased hepatic 
selective uptake of HDL-CE in L-FoxO1,3,4 mice that was observed in our 
studies done in Chapter 2 (Figure 2.3-2.5). As such, these data may suggest 
that there could have been confounding factors in our ezetimibe RCT 
experiment, which we explored in further detail. 
 
3.1.3. Potential Confounding Factors in Ezetimibe RCT Study 
While exploring for potential confounding factors in our ezetimibe RCT 






sample collected. Interestingly, we observed very precise liver 
[3H]cholesterol counts within ezetimibe- and vehicle-treated control groups, 
and we concluded that ezetimibe decreased hepatic [3H]cholesterol levels, 
presumably due to impaired intestinal cholesterol absorption and re-uptake 
by liver (Figure 3.6). In contrast, there was a lot of variability among 
individual mice in the L-FoxO1,3,4 groups (Figure 3.6). We speculate that 
this is due to a technical issue, because while carrying out the in vivo portion 
of the RCT experiment, the four L-FoxO1,3,4 mice with very high hepatic 
[3H]cholesterol levels were injected in succession with the [3H]cholesterol-
loaded foam cells (Figure 3.6). Thus there may have been batch effects, or 
the cell suspension was not homogeneous.  
 
One possible explanation for the lack of any defect in hepatic [3H]cholesterol 
levels found in L-FoxO1,3,4 mice could be differences in hepatic Ldlr 
expression. Using liver samples from the same mice in this RCT cohort, we 
measured hepatic Ldlr expression, as well as hepatic Scarb1 and Foxo1 as 
positive controls. We found a 2-3 fold increase in hepatic Ldlr expression in 
both ezetimibe and vehicle treated L-FoxO1,3,4 mice, while hepatic Foxo1 
and Scarb1 remained decreased (Figure 3.7). LDL receptor can take up not 
only LDL particles, but also chylomicrons and apoE-containing HDL particles 
as well (198, 240). Consequently, [3H]cholesterol that is reabsorbed by 






chylomicrons, which can ultimately then be taken up by the LDL receptor as 
LDL, apoE-HDL, or chylomicron remnants (Supplemental Figure S3.1). As 
such, an increase Ldlr expression in L-FoxO1,3,4 mice could potentially 
explain why we saw no change in hepatic and fecal [3H]cholesterol counts 
between L-FoxO1,3,4 and control mice. However, as this was the first cohort 
we observed this phenotype, further investigation in additional cohorts will 
be required to determine if Ldlr expression is indeed increased in L-
FoxO1,3,4 mice.  
 
3.2. Hepatic FoxOs and Cholesteryl Ester Transfer Protein (CETP) 
3.2.1. Role of CETP and Generation of L-FoxO1,3,4:CETPtg mice 
CETP is responsible for the transfer of esterified cholesterol from HDL 
particles to LDL particles (165, 166). Consequently, this enzyme allows an 
alternative pathway by which HDL-C can be cleared via the LDL receptor. 
Because mice naturally lack CETP, we set out to investigate the effects of 
hepatic FoxOs on RCT in L-FoxO1,3,4 mice expressing a human CETP 
transgene (L-FoxO1,3,4:CETPtg), thereby simulating an in vivo setting 
relevant to human physiology. 
Human CETP transgenic mice were originally developed by Dr. Alan Tall, and 
were characterized to express plasma CETP levels and activities similar to 
those of humans, show reduced HDL levels, and display a humanlike 






FoxO1,3,4 mice to generate L-FoxO1,3,4:CETPtg mice. The four possible 
genotypes were generated (Figure 3.8A): (1) L-FoxO1,3,4, (2) control, (3) 
L-FoxO1,3,4:CETPtg, (4) control:CETPtg. By qPCR, we verified that the 
addition of CETP did not alter hepatic Scarb1 and Lipc expression in either L-
FoxO1,3,4 or control mice (Figure 3.8B). 
 
3.2.2. Analysis of plasma lipoproteins phenotypes in           
L-FoxO1,3,4:CETPtg mice 
The addition of CETP in mice facilitates a second pathway of RCT, through 
LDL receptor (171). To characterize this effect, we analyzed the plasma 
cholesterol profile in L-FoxO1,3,4:CETPtg mice. Total plasma cholesterol 
decreased in L-FoxO1,3,4 mice expressing CETP (L-FoxO1,3,4:CETPtg) when 
compared to L-FoxO1,3,4 mice (Figure 3.9A). However, total plasma 
cholesterol was still higher in L-FoxO1,3,4:CETPtg mice when compared to 
control mice or control mice expressing CETP (control:CETPtg). With regard 
to plasma cholesterol distribution, we found that the increase in large HDL-C  
seen in L-FoxO1,3,4 mice was partially normalized in L-FoxO1,3,4:CETPtg 
mice, but not entirely to the levels seen in control or control:CETPtg mice 
(Figure 3.9B). In a separate cohort of L-FoxO1,3,4:CETPtg and control:CETPtg 
mice, we verified that large HDL-C was indeed higher in L-FoxO1,3,4:CETPtg 
mice than in control:CETPtg mice (data not shown). Taken together, these 






mitigate the accumulation of HDL-C–potentially by allowing some of the 
cholesterol to be transferred to apoB-containing particles and to be cleared 
via the LDL receptor pathway. However, it is not sufficient to completely 
normalize either total plasma cholesterol or plasma cholesterol distribution 
to levels observed in those of control mice. This demonstrates that the 
FoxOàSR-BI/HL pathway plays a consequential role in regulating HDL-C 
levels, even in the presence of CETP. 
  
3.3. Sex Differences in L-FoxO1,3,4 Mice 
An emerging theme in the regulation of hepatic lipid metabolism is the 
involvement of sex hormones and associated receptors (137). Since the 
majority of our experiments were done in male mice, we analyzed a cohort 
of male and female L-FoxO1,3,4 mice and matched controls to determine if 
there were any sex-specific phenotypes in our mice. While sex appeared 
have no effect on total plasma cholesterol levels, we observed sex-specific 
differences in plasma cholesterol distribution (Figure 3.10A-B). We found a 
greater difference of HDL-C (both large and “traditional” sized HDL particles) 
between female L-FoxO1,3,4 and control mice, more so than the difference 
in HDL-C between male L-FoxO1,3,4 and control mice (Figure 3.10A-B). In 
addition, hepatic Lipc expression was significantly higher in female control 
mice compared to male control mice, and there was a bigger difference 






Interestingly, both SR-BI and hepatic lipase are reported to be affected by 
the estrous cycle (137). Taken together, these data suggest that sex may 
play a role in the degree of HDL-C clearance and overall RCT in the setting of 
hepatic FoxO ablation. 
 
3.4. Materials and Methods 
3.4.1. Macrophage-to-Feces RCT in L-FoxO1,3,4 Mice 
3.4.1.1. Ezetimibe Preparation 
It is important to note that ezetimibe is very viscous, and thus difficult to get 
into solution. 0.25mg of ezetimibe was first dissolved in 150 µl of DMSO in 
the bottle, and then transferred to 8.33mL of 0.4% methyl cellulose solution. 
This suspension was then centrifuged at 2000 rpm for 3 min at RT in order 
to consolidate the ezetimibe into a pellet. This solution was then sonicated 
until the ezetimibe pellet at the bottom of tube was completely broken up. 
Since ezetimibe falls out of solution easily, it was necessary to mix the 
solution between each mouse by inverting the tube several times prior 
drawing the needle. The solution was stored at 4°C while shaking on the 
rotor, and centrifugation/sonication was repeated each day prior to use. 
 
3.4.1.2. Macrophage Preparation 
On day one, J774A.1 macrophages (ATCC – TIB-67) were split onto 11 T175 






040-CV) containing FBS (10%, v/v), penicillin (100 µg/ml) and streptomycin 
(100 µg/ml). On day five at 5 pm, radioactive media was prepared. To 
create the base media, 25 µg/mL of AcLDL (Alfa Aesar – J65029) was added 
to “cold media B” - RPMI media containing FBS (1%, v/v), penicillin (100 
µg/m) and streptomycin (100 µg/ml). Commercially available vials of AcLDL 
contain 2 mg, so 80 mL of base media can be made per vial, and I prepared 
160 mL of base media (AcLDL/RPMI) per experiment of ~20 mice. Media 
was prepared in a disposable flask (Corning – 431145) with magnetic stir 
bar. In a hood approved for radioactive materials, the flask was stirring on a 
hot plate set at 40°C. Using a Hamilton syringe, [3H]cholesterol (Perkin 
Elmer –NET139001MC) was carefully added dropwise at a final concentration 
of 5 µCi/ml of base media (i.e. for 160 ml of base media, I added 800 µl of  
[3H]cholesterol, which is sold at 1mCi/ml).  
 
While radioactive media was stirring on the hot plate, J774 macrophages 
were washed 1x with cold media B, and then collected via gentle cell 
scraping. From 11 T175 flasks, I consolidated the cells into two 50mL conical 
tubes. Cells were centrifuged at 1500 rpm for 5 minutes, resuspended, and 
consolidated into 20 mL total of cold media B. Approximately 2 µCi of 
[3H]cholesterol-labeled cells is required per mouse injection (i.e. 
“injected radioactivity”). Thus, I allocated approximately 5,000,000 cells 






I diluted the cells 1:50 (10 µl cells, 490 µl media), then combined 80 µl of 
these diluted cells with 20 µl trypan blue, mixed, and loaded 10 µl onto 
hemocytometer. I counted live (non-blue) cells in four 4x4 squares, 
averaged the counts, divided by 4, divided by 0.8 (80:20 cells to trypan blue 
ratio), multiplied by 10,000, and multiplied by 50 in order to obtain number 
of cells/mL. At this point, the radioactive media was filtered, and then split 
evenly amongst five T175 flasks (~32mL/flask). The appropriate number of 
cells in order to have at least 5 million cells per mouse was then split evenly 
onto the five T175 flasks. Cells were stored in the incubator on top of 
polyvinyl film wrap to prevent radioactive contamination. 
 
3.4.1.3. in vivo Phase 
On day seven, macrophages should be full of 3H-cholesterol. Radioactive 
cells were collected via gentle cell scraping, centrifuged at 1500 rpm for 3 
minutes, consolidated into one conical tube, and washed with 30 µL of “cold 
media C” - RPMI media with HEPES (Corning – 10-041-CV) containing FBS 
(10%, v/v), penicillin (100 µg/ml) and streptomycin (100 µg/ml). Cells were 
centrifuged again at 1500 rpm for 3 minutes, and washed 2 more times (3 
washes total). After the third wash, cells were resuspended in 21 ml of 
“equilibration media” - RPMI 1640 (no HEPES) containing BSA (0.2%), 
penicillin (100 µg/ml) and streptomycin (100 µg/ml). 1 ml of cells were 






cells were split such that 4 ml of cells were distributed onto each of five 
75cm3 ultra low-attachment flasks (Corning – 3814), and supplemented with 
20mL of extra equilibration media. Cells were equilibrated for 4 hours. 
 
During the equilibration period, using the 1 ml aliquot, cells were counted 
using a disposable hemocytometer (in Cyto – DHC-N01-2), and also 
measured for radioactivity (CPM). For scintillation counting, 100 µl of cells 
were diluted 1:10, centrifuged at 3000 rpm for 5 minutes, media was 
aspirated and discarded, and then the cell pellet was dissolved with 1mL of 
0.1 N NaOH and mixed with 4 ml Hi-ionic scintillation fluid (Perkin Elmer - 
6013311). The counts of cells/ml and CPM/ml were used to calculate 
CPM/cell, and ultimately the number of cells required to give 2 µCi of 
[3H]cholesterol per mouse (1 µCi is equivalent to 2220000 DPM, which 
we are assuming is equivalent to approximately 2220000 CPM).  
 
Cells were consolidated via gently cell scraping, and resuspended in RPMI + 
HEPES (NO ADDITIVES) at 4µCi/mL. 0.5 ml of cells @ 4 µCi/ml were 
intraperitoneally injected per mouse. Extreme care should be taken not 
to puncture the intestine or stomach or to have seepage upon needle 
removal. Also, the tube containing the cells should be inverted and 
gently mixed between injections. Mice were injected every 12 minutes, 






and 48 hours after injection. Blood collection tubes contained 5 µl of EDTA + 
5 µl of protease inhibitor cocktail (1 ml H2O per tablet - Roche). Following 
blood collection, blood was centrifuged at 3500 rcf for 10 min, and 
serum/plasma was extracted and stored at -80°C. For WTD-fed experiment 
(Figure 3.1), serum was extracted. For chow-fed experiments (Figure 3.2 + 
Figure 3.5), plasma was extracted. 
 
On day 9, mice were fasted for 4 hours, starting at intervals every 12 
minutes. Immediately following euthanasia, mice were exsanguinated and 
then perfused through the heart with 10 ml of cold PBS. Liver weight was 
recorded, pieces of liver tissue were cut and weights were recorded, and the 
pieces were stored at -80°C. Cages were left out at room temperature until 
feces was dry. Feces was then cleaned of bedding, collected, and stored at -
20°C. 
 
3.4.1.4. Radioactivity Measurements 
For serum/plasma samples, 10 µl of serum/plasma in 4 ml scintillation fluid 
were measured in duplicate for [3H]cholesterol radioactivity counts. For liver 
samples, tissue lipid was extracted via the Bligh-Dyer method. Briefly, liver 
tissue was homogenized in 400µl H2O. 1 ml of methanol, 1ml of chloroform, 
and 0.5 ml of H2O were mixed in, and centrifuged at 1000 rpm for 15 






and resusupended in 500 µl of toluene. 100 µL was taken for scintillation 
counting, and total CPM/organ was calculated.  
 
For feces samples, feces were first dehydrated overnight at 42°C and 
weighed. Feces were then soaked in H2O overnight (1 ml H2O /100 mg 
Feces) at 4°C. The next morning, an equal volume of ethanol was added, 
and the feces were then homogenized. 1 ml of the homogenized sample was 
transferred into a 12 ml glass tube (Fisher; 14-959-35AA) with an airtight 
cap (Fisher; 14-959-36A). 1 ml of ethanol was added to each tube along 
with 200 µl of NaOH, and 50 µl (around 8000 CPM) of [14C]Cholic acid (ARC 
- 0260-50 µCi) as an internal positive control to each sample. I also placed 
50 µl 14C-Cholic acid in a separate tube and went through the entire 
extraction protocol to determine [14C] bile acid recovery. For saponification, 
tubes were heated at 95°C for 2 hr (Vortexed at 30-minute intervals), and 
then cooled to room temperature. 200µl of sample was mixed with 40 µl of 5 
N HCl and counted to measure radioactivity in total fecal sterols.  
 
To measure fecal neutral sterols, the remaining saponified solution was 
mixed with 1.5 ml of H2O and 3 ml hexane, and then centrifuged at 1000 rcf 
for 5 minutes. The top hexane layer was collected into a glass vial, and the 
remaining solution was extracted two more times (three extractions total) 






the interphase, even if it means leaving extra hexane. The extracted hexane 
was dried under N2 gas, while being heated at 60°C to help with drying 
process, and then resusupended in 500 µl of toluene. 2x100 µl aliquots were 
taken and added to 2x4 ml of scintillation fluid for scintillation counting in 
duplicate. The percentage of injected radioactivity per gram of feces was 
calculated.   
 
To measure fecal bile acids, the remaining aqueous portion of the extract 
was mixed with concentrated HCl (approximately 5-6 drops) to adjust the pH 
to < 1. Samples were extracted three times with 3 ml of ethyl acetate in 
similar fashion to the hexane extraction for neutral sterols (i.e. the top ethyl 
acetate layer was collected into a glass vial, and the remaining solution was 
extracted two more times). However, for fecal bile acids, 1 ml of H2O 
was mixed into the remaining aqueous part of the sample after both 
the 1st and 2nd extractions. The 3 extractions of ethyl acetate were pooled 
together, dried under N2 at 60°C, and then resuspended in 500 µl of ethyl 
acetate. 2 x 100 µl aliquots were mixed with 2 x 4 ml scintillation fluid for 
scintillation counting in duplicate. Here, the scintillation counter was set to 
dual mode to collect [3H] and [14C]. The percentage of injected radioactivity 
per gram of feces was calculated. The tube containing only [14C]cholic acid 







3.4.2. Bile Acid Analysis in L-FoxO1,3,4 Mice 
Mice were fasted for 5 hours prior to sacrifice. Total bile acid pool analysis, 
including bile acid pool quantification, composition, and hydrophobicity index 
were performed as described (243). 
 
3.4.3. Generation of L-FoxO1,3,4:CETPtg Mice 
Human CETP transgenic mice were cryorecovered from frozen embryos by 
The Jackson Laboratory (B6.CBA-Tg(CETP)5203Tall/J). These mice were 
crossed with L-FoxO1,3,4 mice to generate L-FoxO1,3,4:CETPtg mice. For 
genotyping, 2 pairs of primers (CETP transgene + internal positive control) 
were mixed together in stock solution of 25µM: 
Primer Sequence 5' --> 3' Primer Type 
19144 CAC ACC ACT GCC TGA TAA CC Transgene Forward 
19145 CTC CTG GCA TAG TGG GTG TC Transgene Reverse 
oIMR7338 CTA GGC CAC AGA ATT GAA AGA 
TCT 
Internal Positive Control 
Forward 
oIMR7339 GTA GGT GGA AAT TCT AGC ATC 
ATC C 
Internal Positive Control 
Reverse 
 
The following cycling protocol was used: 
Step # Temp °C Time Note 
1 94 2 min 
 
2 94 20sec 
 
3 65 15sec -0.5 C per cycle decrease 




repeat steps 2-4 for 10 cycles (Touchdown) 







7 60 15sec 
 




repeat steps 6-8 for 28 cycles 







The transgene band amplifies at 203 bp, whereas the internal positive 
control band amplifies at 324 bp. Note: a band at the size of the transgene 
band can be seen even in CETP negative mice. To distinguish between 
transgenic and wild-type mice, CETP positive mice have a much more 
prominent band at 203 bp, whereas CETP negative mice have a much more 
prominent internal positive control band at 324 bp. 
 
3.4.4. Male vs. Female L-FoxO1,3,4 mice 
Age-matched, 11-12 month old male and female L-FoxO1,3,4 mice and 
littermate controls were utilized for these experiments. Mice were fasted for 
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Figure 3.1. Macrophage-to-Feces RCT in WTD-fed L-FoxO1,3,4 Mice 
L-FoxO1,3,4 mice (n=6) and littermate controls (n=6) were fed WTD for 6 weeks prior to macrophage 
injection. Mice were intraperitoneally injected with 2µCi of 3H-cholesterol-labeled J774 macrophages 
(~4.6 million cells). (A) At the indicated hours after injection, serum was obtained and subjected to 3H-
tracer analysis. Serum data are expressed as total 3H-counts per 10µl of serum. Mice were fasted 4 
hours prior to sacrifice. (B) 48 hours after injection, livers were isolated and cholesterol was extracted 
via Bligh and Dyer method. Livers samples were then subjected to 3H-tracer analysis. Liver data are 
expressed as total 3H-counts per gram of liver weight. (C, D) Feces collected continuously from 0 to 48 
hours after macrophage injection were subjected to 3H-tracer analysis. Neutral sterols and bile acids 
were separated as described in Materials and Methods. Feces data are expressed as percent 3H-
counts per gram of feces weight relative to total injected tracer (~4440000 cpm injected per mouse). *p 
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Figure 3.2. Macrophage-to-Feces RCT in Chow-fed L-FoxO1,3,4 Mice 
L-FoxO1,3,4 mice (n=9) and littermate controls (n=12) were fed chow prior to macrophage injection. 
Mice were intraperitoneally injected with 2µCi of 3H-cholesterol-labeled J774 macrophages (~2.1 million 
cells). (A) At the indicated hours after injection, plasma was obtained and subjected to 3H-tracer 
analysis. Plasma data are expressed as total 3H-counts per 10µl of plasma. Mice were fasted 4 hours 
prior to sacrifice. (B) 47 hours after injection, livers were isolated and cholesterol was extracted via 
Bligh and Dyer method. Livers samples were then subjected to 3H-tracer analysis. Liver data are 
expressed as total 3H-counts per gram of liver weight. (C, D) Feces collected continuously from 0 to 47 
hours after macrophage injection were subjected to 3H-tracer analysis. Neutral sterols and bile acids 
were separated as described in Materials and Methods. Feces data are expressed as percent 3H-
counts per gram of feces weight relative to total injected tracer (~4440000 cpm injected per mouse). *p 






















































Total BA pool:  











































Figure 3.3. Total Bile Acid Pool Analysis in  
L-FoxO1,3,4 Mice 
L-FoxO1,3,4 mice and littermate controls were fasted 5 
hours prior to sacrifice. Liver, bile, gallbladder, and 
small intestine were harvested. (A) Relative hepatic 
gene expression of Cyp7a1 and Cyp8b1 by qPCR. (B) 
Total bile acid pool quantification and composition were 
analyzed as described in Am J Physiol Endocrinol 
Metab. 2017 Aug 1;313(2):E121-E133. TCA denotes 
(C) Total bile acid pool hydrophobicity was analyzed as 
described in Am J Physiol Endocrinol Metab. 2017 Aug 
1;313(2):E121-E133. *p < 0.05, ***p < 0.001 by 
Student’s t-test. Data are presented as mean ± SEM. 
CA, cholic acid; TCA, taurocholic acid; β-MCA, β-
muricholic acid; TβMCA, tauro-β-muricholic acid. 
Species marked in red are 12α-hydroxylated. Those 






























































Plasma Cholesterol (Fed) Day 0 vs. Day 3 
Day 3 Day 0 Day 3 
Figure 3.4. Ezetimibe Treatment in C57BL/6 Mice 
C57BL/6 mice (n=4,5) were were oral gavaged daily with 100ul of ezetimibe solution (0.25mg in 8.33mL 
of 0.4% methyl cellulose) or methyl cellulose alone for 3 days. (A) Approximately 100mg of feces was 
collected per mouse, and fecal cholesterol was extracted via Bligh and Dyer method. (B) Plasma was 
obtained prior to first ezetimibe dose, as well as at time of sacrifice. Plasma cholesterol was then 
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Figure 3.5. Macrophage-to-Feces RCT in Chow-fed L-FoxO1,3,4 mice ± Ezetimibe Treatment  
L-FoxO1,3,4 mice and littermate controls (n=4-5 per group) were oral gavaged daily with 100ul of 
ezetimibe solution (0.25mg in 8.33mL of 0.4% methyl cellulose) or vehicle (methyl cellulose alone) for 3 
days prior to macrophage injection (including the morning of injection), as well as 24 hours after 
injection. Mice were intraperitoneally injected with 0.75µCi of 3H-cholesterol-labeled J774 macrophages 
(~800,000 cells). (A) At the indicated hours after injection, plasma was obtained and subjected to 3H-
tracer analysis. Plasma data are expressed as total 3H-counts per 10µl of plasma. Mice were fasted 4 
hours prior to sacrifice. (B) 48 hours after injection, livers were isolated and cholesterol was extracted 
via Bligh and Dyer method. Livers samples were then subjected to 3H-tracer analysis. Liver data are 
expressed as total 3H-counts per gram of liver weight. (C, D) Feces collected continuously from 0 to 48 
hours after macrophage injection were subjected to 3H-tracer analysis. Neutral sterols and bile acids 
were separated as described in Materials and Methods. Feces data are expressed as percent 3H-
counts per gram of feces weight relative to total injected tracer (~1650000 cpm injected per mouse). *p 











































































Figure 3.6. Liver Data Revisited from Macrophage-to-Feces RCT in Chow-fed L-FoxO1,3,4 Mice ± 
Ezetimibe Treatment  
Liver 3H-counts per gram of liver weight in same mice as figure 3.5B were expressed as individual plots 
for each mouse. The four circled L-FoxO1,3,4 mice with the highest hepatic [3H]cholesterol levels were 
injected in succession with the [3H]cholesterol-loaded foam cells. Average 3H-counts are marked by a 













































































































































Figure 3.7. Hepatic Gene Expression from Macrophage-to-Feces RCT in Chow-fed L-FoxO1,3,4 
Mice ± Ezetimibe Treatment  
Hepatic Foxo1, Scarb1, and Ldlr expression were measured in same mice as figure 3.5B. **p < 0.01, 
***p < 0.001, ****p < 0.0001 between ezetimibe treated L-FoxO1,3,4 and control mice OR vehicle 






































Figure 3.8. Generation of L-FoxO1,3,4:CETPtg Mice  
(A) Representative DNA gel blot of possible scenarios for mouse genotyping CETP transgenic, L-
FoxO1,3,4 mice: (1) Mice that are “floxed” for all three FoxO alleles, and are also expressing one 
copy of a liver-specific Cre, are deficient in hepatic FoxOs (L-FoxO1,3,4); (2) FoxO floxed mice 
without Cre are littermate controls (control); (3) L-FoxO1,3,4 mice expressing one copy of the 
CETP transgene (bottom band) are CETP transgenic, L-FoxO1,3,4 (L-FoxO1,3,4:CETPtg); (4) 
Control mice expressing one copy of the CETP transgene (bottom band) are CETP transgenic, 
control (control:CETPtg). (B) Relative hepatic gene expression of Scarb1 and Lipc by qPCR in 
chow-fed Control (n=8), L-FoxO1,3,4 (n=3), Control:CETPtg (n=8), and L-FoxO1,3,4:CETPtg (n=9) 
mice.  **p < 0.01, ***p < 0.001 by two-way ANOVA, followed by post-hoc Tukey test, using the 















































































Figure 3.9. Plasma Cholesterol Profiles of Chow-fed L-FoxO1,3,4:CETPtg Mice  
(A) Total plasma cholesterol in same as 3.6B after a 5 hour fast. (B) Cholesterol levels in plasma 
fractionated by FPLC in same mice as 3.7A. **p < 0.01 by two-way ANOVA, followed by post-hoc 
Tukey test, using the pooled standard deviation, without Bonferroni correction. Data are 
































































Supplemental Figure S3.1. Proposed Model of Intestinal Radiolabeled Cholesterol Reabsorption and 
“Recycling.” Related to Figure 3.7.  
(1) Radiolabeled cholesterol (represented as “3H”) is taken up by the liver (via SR-BI), where it is either 
converted to bile acids or transported directly into the bile. (2) From hepatocytes, Bile and bile acids 
eventually make their way to the intestine, where they help emulsify dietary lipids to form micelles. The 
radioactive micellar cholesterol is absorbed from the intestinal lumen predominantly via the NPC1L1 
transporter. (3) From enterocytes, this radioactive cholesterol can be either incorporated into chylomicrons 
(that are subsequently secreted into the lymph and then into the circulation) or incorporated into HDL (that is 
secreted directly into the circulation). (4) From the circulation, radiolabeled cholesterol make their way back 
to the liver. However, radiolabeled cholesterol can now be incorporated into chylomicron remnants, LDL, and 

















4.1. Macrophage-to-Feces RCT in L-FoxO1,3,4 mice 
4.1.1. Intrahepatic Cholesterol Sensing and Regulation 
The potential increase in hepatic Ldlr expression in L-FoxO1,3,4 mice (Figure 
3.7) suggests that hepatic FoxO ablation may have an effect on hepatocyte 
cholesterol sensing and regulation. Previously, liver-specific FoxO1 single 
knock-out mice have been reported to have a 60% increase in Srebp-2 
mRNA compared to that of control mice (245). SREBP-2 is a transcription 
factor that promotes the expression of many genes involved in cholesterol 
homeostasis, including LDL receptor, Pcsk9, and many different cholesterol 
biosynthesis enzymes (246-248). Since intrahepatic cholesterol levels induce 
the expression of many of the genes involved in the SREBP-2 signaling 
pathway, and hepatic FoxOs regulate both hepatic HDL-C uptake and 
cholesterol catabolism as bile acids, it is feasible that some of the SREBP-2 
signaling pathway genes are indirectly modulated by hepatic FoxOs. 
Therefore, it will be of interest to further investigate genes involved in the 
SREBP-2 signaling pathway in L-FoxO1,3,4 mice, especially in the setting of 
high plasma cholesterol (i.e. WTD-feeding), in order to determine if there 
are additional direct or indirect hepatic FoxO targets that play a role in 









4.1.2. Additional Confounding Factors  
We suspected that there were additional potential confounding factors and 
assay limitations that could have affected our macrophage-to-feces RCT 
results. First, given that we used exogenous, non-native macrophages, we 
cannot assume that the injected macrophages “behaved” as native 
macrophages would. As such, there could be unaccountable changes in 
macrophage localization and cholesterol efflux capacity. This is particularly 
relevant to our studies since, compared to control mice, L-FoxO1,3,4 mice 
have a significantly different lipoprotein pool in terms of the size and content 
of HDL particles.  
 
Second, it is possible there were differences in tracer specific activity 
between L-FoxO1,3,4 and control mice. Assuming all mice received the same 
amount of radioactive macrophages, any [3H]cholesterol that is effluxed 
from macrophage foam cells onto the lipoprotein pool would be diluted 
because L-FoxO1,3,4 mice are expected to have higher total plasma 
cholesterol levels than that of control mice (Figure 4.1). As such, the 
probability that [3H]cholesterol is taken up by hepatocytes would 
theoretically be much lower in L-FoxO1,3,4 mice than in control mice – not 
only due to low SR-BI (and possibly high LDL receptor) expression, but also 
because the radioactive cholesterol would be competing with a higher pool of 






explain why there was more variability of [3H]cholesterol levels in the L-
FoxO1,3,4 livers compared to those of controls livers. However, this 
hypothesis could not explain why we did not see lower [3H]cholesterol levels 
in the L-FoxO1,3,4 mice livers compared to that of control livers. We would 
expect that low tracer specific activity, combined with low SR-BI levels would 
cause an even greater decrease in hepatic HDL-C clearance, and thus lower 
[3H]cholesterol levels in the L-FoxO1,3,4 mice livers compared to that of 
control.  
 
Finally, we cannot rule out the possibility of technical error; namely, the 
possibility that the mice received an unequal injection of radioactive 
macrophages due to batch effects or non-homogenous cell suspension. In 
order to account for this possibility, we reinterpreted our data by adding the 
total 3H-tracer counts (in CPM) from what was collected (blood, liver, and 
feces), and expressed each measurement as a percentage of the total CPMs 
collected (Figure 4.2). Blood and liver values were based off of assumptions 
for total blood volume (based on 58.5 ml of mouse blood per kilogram of 
body weight) and liver weight (based on data collected from L-FoxO1,3,4 
and control mice). In this analysis, we observed that fecal 3H-tracer counts 
in the ezetimibe-treated control mice tended to be higher than that of the 
ezetimibe-treated L-FoxO1,3,4 mice. This would be consistent with impaired 






be required in future studies to determine if this is an accurate 
representation of the data.  
 
4.1.3. Summary of Cholesterol Phenotypes 
Taking these potential scenarios into account, it is important to also consider 
all the reported phenotypes of L-FoxO1,3,4 mice relative to controls: L-
FoxO1,3,4 mice have high cholesterol levels on apoE-containing HDL 
particles; low Scarb1 and Lipc expression, and thus low uptake of HDL-C into 
the liver; potentially elevated Ldlr expression, and thus high uptake of 
cholesterol from other particles (LDLs, chylomicron remnants, apoE-HDL); 
high cholesterol synthesis, presumably due to relatively low uptake of HDL-
C; and low cholesterol catabolism into bile acids, which theoretically causes 
low intestinal cholesterol reabsorption. With such an intricate system that 
affects the expression of different factors across multiple organs, it is clear 
that future discovery of additional hepatic FoxO targets, both indirect and 
direct, will assist in determining whether macrophage-to-feces RCT is 
impaired in L-FoxO1,3,4 mice. 
 
Finally, from our fractionated plasma samples via FPLC, we also observed 
that, compared to control mice, L-FoxO1,3,4 mice have somewhat higher 
levels of plasma apoB, the major structural apolipoprotein of LDL 






predominately in fractions where there seems to be little to no difference in 
plasma cholesterol between genotypes (i.e. fractions 45-50), suggesting that 
there is no difference in LDL cholesterol between genotypes. Since the 
majority of excess plasma cholesterol in L-FoxO1,3,4 mice elutes primarily 
with apoA-I/apoE particles, rather than apoB particles, we attribute the 
plasma cholesterol phenotype to the defective HDL-C clearance that we 
observed. Nevertheless, we are interested in the causes of the increased 
apoB levels in L-FoxO1,3,4 mice, and will need to further investigate this 
phenotype to understand its effects on cholesterol metabolism and overall 
RCT. Interestingly, it has been reported that the noncatalytic function of 
hepatic lipase provides an alternate clearance pathway for apoB containing 
lipoproteins that is independent of the LDL receptor and that contributes to 
the clearance of high density lipoproteins (126, 249). It is possible that low 
hepatic lipase levels in the setting of hepatic FoxO ablation is the cause of 
the increased plasma apoB levels in L-FoxO1,3,4 mice. Thus, it will be 
informative to determine if hepatic lipase rescue is sufficient to mitigate the 
increased apoB levels seen in L-FoxO1,3,4 mice.  
 
4.2. Hepatic FoxOs and Cholesteryl Ester Transfer Protein (CETP) 
From the cohorts that were analyzed, we concluded that the addition of 
CETP – in the setting of hepatic FoxO ablation – mitigates the accumulation 






normalize either total plasma cholesterol or plasma cholesterol distribution 
to levels observed in those of control mice. As hepatic cholesterol uptake 
relies more heavily on the LDL receptor with the addition of CETP, we expect 
that L-FoxO1,3,4:CETPtg mice will have increased cholesterol clearance by 
liver and cholesterol excretion by macrophage-to-feces RCT when compared 
to those of L-FoxO1,3,4 mice (assuming macrophage-to-feces RCT is indeed 
impaired in L-FoxO1,3,4 mice). However, we do not expect the addition of 
CETP to completely restore these phenotypes to the levels seen in 
control:CETPtg mice because of the overwhelming effects of Hepatic FoxOs on 
hepatic cholesterol clearance. 
 
A previous study has shown that introducing human CETP via adeno-
associated virus (AAV) in SR-BI deficient mice restores the impaired 
macrophage-to-feces RCT phenotype back to normal (171). While L-
FoxO1,3,4 mice also have impaired SR-BI expression, we expect that this 
will not be the case in L-FoxO1,3,4:CETPtg mice for two reasons; (1) It is 
possible that the AAV-mediated approach used in the study caused the RCT 
phenotype to be exaggerated due to the acute expression of CETP beyond 
physiologically relevant levels (unlike CETP transgenic mice, which express 
human CETP at physiologically relevant levels from birth) (241); (2) The 
mice used in the study were deficient of only SR-BI, whereas L-FoxO1,3,4 






their bile acid metabolism, which collectively may affect overall RCT to a 
higher degree. Thus, we believe that by regulating SR-BI, HL, and 
potentially other undiscovered factors, hepatic FoxOs are required for 
optimal RCT activity.  
 
4.3. Sex Differences in L-FoxO1,3,4 Mice 
The FPLC curves from our mixed-sex cohort of L-FoxO1,3,4 mice and 
matched controls revealed a striking difference in cholesterol distribution 
between female L-FoxO1,3,4 and control mice when compared to that of 
male L-FoxO1,3,4 and control mice (Figure 3.10B). The data suggest that 
there may be a sexual dimorphism in cholesterol homeostasis between male 
and female L-FoxO1,3,4 mice. As such, we hypothesize that, when 
compared to their gender-matched controls, female L-FoxO1,3,4 mice have 
more impaired hepatic cholesterol clearance than males of that genotype do. 
To support our hypothesis, we also observed nearly 2-fold elevated levels of 
hepatic Lipc expression in female control mice compared to that of male 
control mice, with relatively similar Lipc expression between female and 
male L-FoxO1,3,4 mice (Figure 3.10C). Given HL’s role in aiding in hepatic 
cholesterol clearance, a larger difference in Lipc expression between female 
genotypes (compared to that of male genotypes) could account for a 
difference in hepatic cholesterol clearance between male and female mice. 






certainly feasible that hepatic estrogen signaling played a role in the degree 
of Lipc expression seen in our mice. However, it is important to note that the 
mice analyzed in these experiments were studied at 10-11 months of age, 
which is within the transition period of reproductive senescence. Female 
mice are reported to approach the endocrine equivalent of human 
perimenopause by 9 months of age, and between 9 and 12 months, become 
reproductively senescent (250, 251). If the mice in our experiment have 
reached reproductive senescence, our data may suggest that there are 
additional undiscovered, sex-specific modulators of Lipc expression, and 
overall HDL-C metabolism. It is thus important to consider studying future 
cohorts at different periods of sexual maturity in order to determine the full 
spectrum of sexual dimorphism, in the setting of hepatic FoxO ablation. 
 
4.4. Final Remarks 
As hepatic insulin signaling inhibits hepatic FoxO activity, we can represent 
the ablation of hepatic FoxOs in L-FoxO1,3,4 mice as an animal model of 
increased insulin signaling. Through this animal model, we have 
demonstrated that the hepatic insulinàFoxO signaling pathway is able to 
regulate HDL-C homeostasis. While important questions remain – especially 
regarding the impact of hepatic FoxO ablation on overall RCT – we now 
understand that the insulinàFoxO signaling pathway plays a role in the 






prevention. As such, further characterization of this pathway, especially 
discovery of downstream hepatic FoxO targets, may bridge the gap between 
hepatic insulin signaling and cholesterol homeostasis, thereby increasing our 
understanding of the underlying mechanisms between insulin resistance, 









































































Figure 4.1. Potential Confounder: Differences in Tracer Specific Activity 
Since L-FoxO1,3,4 mice are expected to have higher total plasma cholesterol levels than that of control 
mice, any [3H]cholesterol that is effluxed from macrophage foam cells onto the lipoprotein pool would 
be diluted. As such, the probability that [3H]cholesterol is taken up by hepatocytes would theoretically 
be much lower in L-FoxO1,3,4 mice than in control mice – not only due to low SR-BI (and possibly high 
LDL receptor) expression, but also because the radioactive cholesterol would be competing with a 
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Figure 4.2. Potential Confounder: Unequal Injection of Radiolabeled Macrophages 
In order to account for unequal injection of radiolabeled macrophages between mice, we reinterpreted 
our data by adding the total 3H-tracer counts (in CPM) from what was collected (blood, liver, and feces), 
and expressed each measurement as a percentage of the total CPMs collected (. Blood and liver 
values were based off of assumptions for total blood volume (based on 58.5 ml of mouse blood per 
kilogram of body weight) and liver weight (based on data collected from L-FoxO1,3,4 and control mice).  
CPMs from  
Total Blood Volume + CPMs from Total Liver + CPMs from Total Feces Total CPMs = 
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